WO2002064755A2 - Post-partum mammalian placenta, its use and placental stem cells therefrom - Google Patents
Post-partum mammalian placenta, its use and placental stem cells therefrom Download PDFInfo
- Publication number
- WO2002064755A2 WO2002064755A2 PCT/US2002/004282 US0204282W WO02064755A2 WO 2002064755 A2 WO2002064755 A2 WO 2002064755A2 US 0204282 W US0204282 W US 0204282W WO 02064755 A2 WO02064755 A2 WO 02064755A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- placenta
- cells
- stem cells
- cell
- perfused
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0462—Placental blood, umbilical cord blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/14—Female reproductive, genital organs
- A61M2210/1433—Uterus
- A61M2210/1458—Placenta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/14—Female reproductive, genital organs
- A61M2210/1433—Uterus
- A61M2210/1466—Umbilical cord
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
Definitions
- the present invention relates to methods of exsanguinating and perfusing a placenta following expulsion from the uterus, e.g., after birth.
- the present invention relates to methods of treating and culturing an isolated placenta for the propagation of embryonic-like stem cells originating -from the placenta and exogenous sources.
- the present invention further relates to the use of a cultured placenta as a bioreactor to produce biological materials or culture cells, tissues and organoids.
- the present invention also relates to stem cell collection and propagation, and in particular, to the collection of embryonic-like stem cells and other multipotent stem cells from placentas.
- the present invention relates to embryonic-like stem cells originating from a post-partum placenta.
- Human stem cells are totipotential or pluripotential precursor cells capable of generating a variety of mature human cell lineages. This ability serves as the basis for the cellular differentiation and specialization necessary for organ and tissue development. Recent success at transplanting such stem cells have provided new clinical tools to reconstitute and/or supplement bone marrow after myeloablation due to disease, exposure to toxic chemical and/or radiation. Further evidence exists that demonstrates that stem cells can be employed to repopulate many, if not all, tissues and restore physiologic and anatomic functionality. The application of stem cells in tissue engineering, gene therapy delivery and cell therapeutics is also advancing rapidly.
- stem cells Many different types have been characterized. For example, embryonic stem cells, embryonic germ cells, adult stem cells or other committed stem cells or progenitor cells are known. Certain stem cells have not only been isolated and characterized but have also been cultured under conditions to allow differentiation to a limited extent. A basic problem remains, however, in that obtaining sufficient quantities and populations of human stem cells which are capable of differentiating into all cell types is near impossible. Stem cells are in critically short supply. These are important for the treatment of a wide variety of disorders, including malignancies, inborn errors of metabolism, hemoglobinopathies, and immunodeficiences. It would be highly advantageous to have a source of more embryonic stem cells.
- hMSC human mesenchymal stem cell
- Homogeneous hMSC compositions are obtained by positive selection of adherent marrow or periosteal cells that are free of markers associated with either hematopoietic cell or differentiated mesenchymal cells.
- These isolated mesenchymal cell populations display epitopic characteristics associated with mesenchymal stem cells, have the ability to regenerate in culture without differentiating, and have the ability to differentiate into specific mesenchymal lineages when either induced in vitro or placed in vivo at the site of damaged tissue.
- the drawback of such methods is that they require harvesting of marrow or periosteal cells from a donor, from which the MSCs must be subsequently isolated.
- Hu et al.. discloses human amniotic epithelial cells derived from placenta at delivery that are isolated, cultured, cryopreserved for future use, or induced to differentiate.
- a placenta is harvested immediately after delivery and the amniotic membrane separated from the chorion, e.g., by dissection.
- Amniotic epithelial cells are isolated from the amniotic membrane according to standard cell isolation techniques.
- the disclosed cells can be cultured in various media, expanded in culture, cryopreserved, or induced to differentiate.
- Hu et al. discloses that amniotic epithelial cells are multipotential (and possibly pluripotential), and can differentiate into epithelial tissues such as corneal surface epithelium or vaginal epithelium.
- the drawback of such methods is that they are labor-intensive and the yield of stem cells is very low.
- amniotic epithelial cells must be first isolated from the amnion by dissection and cell separation techniques, then cultured and expanded in vitro.
- Umbilical cord blood (cord blood) is a known alternative source of hematopoietic progenitor stem cells.
- Stem cells from cord blood are routinely cryopreserved for use in hematopoietic reconstitution, a widely used therapeutic procedure used in bone marrow and other related transplantations (see e.g., Boyse et al, U.S. 5,004,681, "Preservation of Fetal and Neonatal Hematopoietin Stem and Progenitor Cells of the Blood", Boyse et al, U.S. Patent No.
- Naughton et al. U.S. Patent No. 5,962,325 entitled “Three-dimensional stromal tissue cultures” issued October 5, 1999 discloses that fetal cells, including fibroblast-like cells and chondrocyte-progenitors, may be obtained from umbilical cord or placenta tissue or umbilical cord blood.
- Naughton et al. U.S. Patent No. 5,962,325 discloses that such fetal stromal cells can be used to prepare a "generic" stromal or cartilaginous tissue. Naughton et al.
- a "specific" stromal tissue may be prepared by inoculating a three-dimensional matrix with fibroblasts derived from a particular individual who is later to receive the cells and/or tissues grown in culture in accordance with the disclosed methods.
- the drawback of such an approach is that it is labor intensive. According to the methods disclosed in Naughton et al, to recover fetal stromal cells from the umbilical cord or placenta requires dissection of these tissues, mincing of the tissue into pieces and disaggregation. Furthermore, to obtain adequate amounts of the fetal stromal cells from umbilical cord blood, as well as the umbilical cord and placenta, requires further expansion ex vivo.
- Emerson et al (Emerson et al, U.S. Patent No. 6,326,198 entitled “Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells", issued December 4, 2001); discloses methods, and culture media conditions for ex vivo culturing of human stem cell division and/or the optimization of human hematopoietic progenitor stem cells.
- human stem cells or progenitor cells derived from bone marrow are cultured in a liquid culture medium that is replaced, preferably perfused, either continuously or periodically, at a rate of 1 ml of medium per ml of culture per about 24 to about 48 hour period. Metabolic products are removed and depleted nutrients replenished while maintaining the culture under physiologically acceptable conditions.
- Rraus et al. discloses that a predetermined target population of cells may be selectively expanded by introducing a starting sample of cells from cord blood or peripheral blood into a growth medium, causing cells of the target cell population to divide, and contacting the cells in the growth medium with a selection element comprising binding molecules with specific affinity (such as a monoclonal antibody for CD34) for a predetermined population of cells (such as CD34 cells), so as to select cells of the predetermined target population from other cells in the growth medium.
- a selection element comprising binding molecules with specific affinity (such as a monoclonal antibody for CD34) for a predetermined population of cells (such as CD34 cells), so as to select cells of the predetermined target population from other cells in the growth medium.
- Rodgers et al discloses methods for ex vivo culture of hematopoietic and mesenchymal stem cells and the induction of lineage-specific cell proliferation and differentiation by growth in the presence of angiotensinogen, angiotensin I (AT), Al analogues, Al fragments and analogues thereof, angiotensin II (All), AH analogues, AH fragments or analogues thereof or All AT 2 type 2 receptor agonists, either alone or in combination with other growth factors and cytokines.
- angiotensinogen angiotensin I
- AT angiotensin I
- Al fragments and analogues thereof angiotensin II
- All AH analogues, AH fragments or analogues thereof or All AT 2 type 2 receptor agonists
- the stem cells are derived from bone marrow, peripheral blood or umbilical cord blood.
- the drawback of such methods is that such ex vivo methods for inducing proliferation and differentiation of stem cells are time-consuming, as discussed above, and also result in low yields of stem cells.
- Naughton et al (U.S. Patent No. 6,022,743 entitled “Three-dimensional culture of pancreatic parenchymal cells cultured living stromal tissue prepared in vitro,” issued February 8, 2000) discloses a tissue culture system in which stem cells or progenitor cells (e.g., stromal cells such as those derived from umbilical cord cells, placental cells, mesenchymal stem cells or fetal cells) are propagated on three-dimensional support rather than as a two-dimensional monolayer in, e.g., a culture vessel such as a flask or dish.
- stem cells or progenitor cells e.g., stromal cells such as those derived from umbilical cord cells, placental cells, mesenchymal stem cells or fetal cells
- stem cells Because of restrictions on the collection and use of stem cells, and the inadequate numbers of cells typically collected from cord blood, stem cells are in critically short supply. Stem cells have the potential to be used in the treatment of a wide variety of disorders, including malignancies, inborn errors of metabolism, hemoglobinopathies, and immunodeficiencies. There is a critical need for a readily accessible source of large numbers of human stem cells for a variety of therapeutic and other medically related purposes. The present invention addresses that need and others.
- the present invention relates to a mammalian placenta, preferably human, which following expulsion from the uterus has been treated and cultured to produce multipotent stem cells (e.g., committed progenitor cells), embryonic-like stem cells and other biological materials.
- multipotent stem cells e.g., committed progenitor cells
- the present invention provides methods of perfusing and exsanguinating a placenta post birth.
- the present invention provides methods of exsanguinating and perfusing a placenta under sterile conditions for a period of at least two to greater than forty-eight hours following expulsion of the placenta from the uterus.
- the placenta is perfused with a solution containing factors to enhance the exsanguination, such as anticoagulant factors.
- the placenta is perfused with a solution containing factors to enhance the sterile conditions, such as antimicrobial and antiviral agents.
- the placenta is perfused with a solution containing growth factors.
- Such solutions which contains growth factors and other culture components but without anticoagulants are referred to as culture solution.
- the placenta is perfused to remove blood, residual cells, proteins and any other residual material. The placenta may be further processed to remove material debris. Perfusion is normally continued with an appropriate perfusate for at least two to more than twenty-four hours.
- the placenta is perfused for at least 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 hours prior to the collection of stem cells.
- the perfusate collected from any of these time points may also provide a source of embryonic-like stem cells.
- cord blood which contains predominantly CD34+ and CD38+ hematopoietic progenitor cells.
- CD34+ and CD38- hematopoietic progenitor cells can be isolated from the placenta along with CD34+ and CD38- cells.
- CD34- and CD38- cells can be isolated from the placenta along with the aforementioned cells.
- the present invention relates to an isolated placenta that has been exsanguinated and perfused under sterile conditions.
- the invention provides an isolated placenta that has been exsanguinated and perfused to remove all residual cells and cultured for a period of two to twenty four hours following expulsion from the uterus.
- the present invention also provides an isolated placenta that has been treated and cultured to result in a viable organ capable of producing embryonic-like stem cells, progenitor cells and other biological materials.
- the present invention relates to a stem cell producing apparatus which comprises a post-partum mammalian placenta which has been exsanguinated and perfused, a means for incubating or culturing the placenta; and a means for detecting stem cells, fn another embodiment, the apparatus of the invention further comprises a collection device and/or a means for separating the collected cells. In another embodiment, the apparatus of the invention further comprises a means for monitoring and adjusting the culture conditions and collection of cells.
- the present invention also provides methods of incubating and culturing an isolated exsanguinated placenta under the appropriate conditions to allow for the production of embryonic-like stem cells that originate from the placenta.
- embryonic-like stem cells are obtained from a placenta following expulsion from the uterus.
- the placenta is exsanguinated and perfused for a period of at least two to twenty four hours to remove all residual cells.
- the exsanguinated placenta is then cultured under the appropriate conditions to allow for the production of endogenous stem cells originating from the placenta, including, but not limited to embryonic-like stem cells, and pluripotent or multipotent stem cells.
- the exsanguinated placenta is cultured in the presence of growth factors, such as PDGF and EGF.
- the present invention further provides methods of treating and culturing an isolated placenta for use as a bioreactor for the propagation of endogenous stem cells originating from the placenta.
- the present invention provides methods of treating and culturing an isolated placenta for use as a bioreactor for the propagation of exogenous cells and biological materials, e.g., antibodies, proteins, oligonucleotides, hormones, viruses, cytokines and enzymes.
- the present invention also provides propagation and collection of embryonic-like stem cells and other pluripotent and multipotent stem cells from placentas.
- the cultured placenta may be used repeatedly as a bioreactor and may be cultured over a period of days, months and even years.
- the cultured placenta may be maintained by periodically or continuously removing a portion of a culture medium or perfusion fluid that is introduced into the system and from which the propagated cells or produced biological materials maybe recovered, and replaced with fresh medium or perfusate liquid.
- the invention provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells, progenitor cells, pluripotent cells and multipotent cells.
- the endogenous cells propagated in the placental bioreactor may be collected, and/or bioactive molecules recovered from the perfusate, culture medium or from the placenta cells themselves.
- the invention provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate exogenous cells.
- the invention relates to an isolated placenta which contains a cell not derived from the placenta, wherein the engraftment of said cell into the placenta may stimulate the placenta to produce embryonic-like stem cells or wherein the engrafted cell produces signals, such a cytokines and growth factors, which may stimulate the placenta to produce stem cells.
- the placenta may be engrafted with cells not placental in origin obtained from the infant associated with the placenta.
- the placenta may be engrafted with cells not placental in origin obtained from the parents or siblings of the infant associated with the placenta.
- the exogenous cells propagated in the placental bioreactor may be collected, and or bioactive molecules recovered from the perfusate, culture medium or from the placenta cells themselves.
- the present invention provides embryonic-like stem cells that originate from a placenta.
- the embryonic-like stem cells of the invention maybe characterized by measuring changes in morphology and cell surface markers using techniques such as flow cytometry and immunocytochemistry, and measuring changes in gene expression using techniques, such as PCR.
- such embryonic-like stem cells may be characterized by the presence of the following cell surface markers: CD10+, CD29+, CD34-, CD38-, CD44+, CD45-, CD54+, CD90+, SH2+, SH3+, SH4+, SSEA3-, SSEA4-, OCT-4+, and ABC-p-h
- such embryonic-like stem cells may be characterized by the presence of cell surface markers OCT-4+ and APC-p+.
- Embryonic-like stem cells originating from placenta the have characteristics of embryonic stem cells but are not derived from the embryo.
- the invention encompasses OCT-4+ and ABC-p+ cells that are undifferentiated stem cells that are isolated from post- partum perfused placenta.
- Such cells are as versatile (e.g., pluripotent) as human embryonic stem cells.
- pluripotent e.g., pluripotent
- a number of different pluripotent or multipotent stem cells can be isolated from the perfused placenta at different time points e.g., CD34+ /CD38+, CD34+ /CD38-, and CD34-/CD38- hematopoietic cells.
- human placenta is used post-birth as the source of embryonic-like stem cells.
- the invention provides a method for isolating other embryonic-like and/or multipotent or pluripotent stem cells from an extractant or perfusate of a exsanguinated placenta.
- the present invention relates to pharmaceutical compositions which comprise the embryonic-like stem cells of the invention.
- the present invention further relates to an isolated homogenous population of human placental stem cells which has the potential to differentiate into all cell types.
- the invention also encompasses pharmaceutical compositions have high concentrations (or larger populations) of homogenous hematopoietic stem cells including but not limited to CD34+ /CD38- cells; and CD34-/ CD38- cells one or more of these cell populations can be used with or as a mixture with cord blood hematopoietic cells i.e., CD34+/CD38+ hematopoietic cells for transplantation and other uses.
- the stem cells obtained by the methods of the invention have a multitude of uses in transplantation to treat or prevent disease. In one embodiment of the invention, they are used to renovate and repopulate tissues and organs, thereby replacing or repairing diseased tissues, organs or portions thereof. 3.1. DEFINITIONS
- the term “bioreactor” refers to an ex vivo system for propagating cells, producing or expressing biological materials and growing or culturing cells tissues, organoids, viruses, proteins, polynucleotides and microorganisms.
- embryonic stem cell refers to a cell that is derived from the inner cell mass of a blastocyst (e.g., a 4- to 5-day-old human embryo) and that is pluripotent.
- embryonic-like stem cell refers to a cell that is not derived from the inner cell mass of a blastocyst.
- an "embryonic-like stem cell” may also be referred to as a "placental stem cell.”
- An embryonic-like stem cell is preferably pluripotent.
- the stem cells which may be obtained from the placenta include embryonic-like stem cells, multipotent cells, and committed progenitor cells. According to the methods of the invention, embryonic-like stem cells derived from the placenta may be collected from the isolated placenta once it has been exsanguinated and perfused for a period of time sufficient to remove residual cells.
- exsanguinated refers to the removal and/or draining of substantially all cord blood from the placenta.
- exsanguination of the placenta can be achieved by, for example, but not by way of limitation, draining, gravity induced efflux, massaging, squeezing, pumping, etc.
- exsanguination of the placenta may further be achieved by perfusing, rinsing or flushing the placenta with a fluid that may or may not contain agents, such as anticoagulants, to aid in the exsanguination of the placenta.
- perfuse refers to the act of pouring or passaging a fluid over or through an organ or tissue, preferably the passage of fluid through an organ or tissue with sufficient force or pressure to remove any residual cells, e.g., non- attached cells from the organ or tissue.
- perfusate refers to the fluid collected following its passage through an organ or tissue. In a preferred embodiment, the perfusate contains one or more anticoagulants.
- exogenous cell refers to a "foreign” cell, i.e., a heterologous cell (i.e., a "non-self cell derived from a source other than the placental donor) or autologous cell (i.e., a "self cell derived from the placental donor) that is-derived from an organ or tissue other than the placenta.
- heterologous cell i.e., a "non-self cell derived from a source other than the placental donor
- autologous cell i.e., a "self cell derived from the placental donor
- organ or tissue refers to an aggregation of one or more cell types assembled in superficial appearance or in actual structure as any organ or gland of a mammalian body, preferably the human body.
- multipotent cell refers to a cell that has the capacity to grow into any of subset of the mammalian body's approximately 260 cell types. Unlike a pluripotent cell, a multipotent cell does not have the capacity to form all of the cell types.
- pluripotent cell refers to a cell that has complete differentiation versatility, i.e., the capacity to grow into any of the mammalian body's approximately 260 cell types.
- a pluripotent cell can be self-renewing, and can remain dormant or quiescent within a tissue. Unlike a totipotent cell (e.g., a fertilized, diploid egg cell), an embryonic stem cell cannot usually form a new blastocyst.
- progenitor cell refers to a cell that is committed to differentiate into a specific type of cell or to form a specific type of tissue.
- stem cell refers to a master cell that can reproduce indefinitely to form the specialized cells of tissues and organs.
- a stem cell is a developmentally pluripotent or multipotent cell.
- a stem cell can divide to produce two daughter stem cells, or one daughter stem cell and one progenitor (“transit”) cell, which then proliferates into the tissue's mature, fully formed cells.
- totipotent cell refers to a cell that is able to form a complete embryo (e.g., a blastocyst).
- Figure 1 is a cross-sectional view of the cannulation of the vein and artery of a placenta to perfuse the placenta and then collect the perfusate.
- Figures 2a-e are schematics showing the collection, clamping, perfusion, collection and storage of an exsanguinated and perfused placenta.
- Figure 3 is a cross-sectional schematic of a perfused placenta in a device for use as a bioreactor.
- Figure 4 is a selection scheme for sorting cells, including embryonic-like stem cells, retrieved from a perfused placenta.
- the placenta after birth contains quiescent cells which can be activated if the placenta is properly processed after birth. For example, after expulsion from the womb, the placenta is exsanguinated as quickly as possible to prevent or minimize apoptosis. Subsequently, as soon as possible after exsanguination the placenta is perfused to remove blood,- residual cells, proteins, factors and any other materials present in the organ. Materials debris may also be removed from the placenta. Perfusion is normally continued with an appropriate perfusate for at least two to more than twenty-four hours. In several additional embodiments the placenta is perfused for at least 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 hours.
- this invention is based at least in part on the discovery that the cells of a post-partum placenta can be activated by exsanguination and perfusion for a sufficient amount of time. Therefore, the placenta can readily be used as a rich and abundant source of embryonic-like stem cells, which cells can be used for research, including drug discovery, treatment and prevention of diseases, in particular transplantation surgeries or therapies, and the generation of committed cells, tissues and organoids.
- the human placental stem cells produced by the exsanguinated, perfused and/or cultured placenta are pluripotent stem cells that can readily be differentiated into any desired cell type.
- the present invention relates to methods of treating and culturing an isolated placenta for use as a bioreactor for the production and propagation of embryonic-like stem cells originating from the placenta or from exogenous sources.
- the present invention also relates to the use of a cultured placenta as a bioreactor to produce biological materials, including, but not limited to, antibodies, hormones, cytokines, growth factors and viruses.
- the present invention also relates to methods of collecting and isolating the stem cells and biological materials from the cultured placenta.
- the present invention relates to methods of perfusing and exsanguinating an isolated placenta once it has been expunged from a uterus, to remove all residual cells.
- the invention further relates to culturing the isolated and exsanguinated placenta under the appropriate conditions to allow for the production and propagation of embryonic-like stem cells.
- the present invention provides a method of extracting and recovering embryonic- like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta.
- Embryonic-like stem cells have characteristics of embryonic stem cells but are not derived from the embryo. Such cells are as versatile (e.g., pluripotent) as human embryonic stem cells.
- human placenta is used post-birth as the source of embryonic-like stem cells.
- embryonic-like stem cells are extracted from a drained placenta by means of a perfusion technique that utilizes either or both of the umbilical artery and umbilical vein.
- the placenta is preferably drained by exsanguination and collection of residual blood (e.g., residual umbilical cord blood).
- the drained placenta is then processed in such a manner as to establish an ex vivo, natural bioreactor environment in which resident embryonic-like stem cells within the parenchyma and extravascular space are recruited.
- the embryonic-like stem cells migrate into the drained, empty microcirculation where, according to the methods of the invention, they are collected, preferably by washing into a collecting vessel by perfusion.
- a human placenta is recovered shortly after its expulsion after birth and, in certain embodiments, the cord blood in the placenta is recovered.
- the placenta is subjected to a conventional cord blood recovery process.
- cord blood recovery may be obtained commercially, e.g., LifeBank Inc., Cedar Knolls, N.J., NiaCord, Cord Blood Registry and Cryocell.
- the cord blood can be drained shortly after expulsion of the placenta.
- the placenta is drained of cord blood.
- the placenta stored may be under sterile conditions and at either room temperature or at a temperature of 5 to 25 °C (centigrade).
- the placenta may be stored for a period of longer than forty eight hours, and preferably for a period of four to twenty-four hours prior to perfusing the placenta to remove any residual cord blood.
- a placenta is transported from the delivery or birthing room to another location, e.g. , a laboratory, for recovery of the cord blood and/or drainage and perfusion.
- the placenta is preferably transported in a sterile, thermally insulated transport device
- the placenta (maintaining the temperature of the placenta between 20-28 °C), for example, by placing the placenta, with clamped proximal umbilical cord, in a sterile zip-lock plastic bag, which is then placed in an insulated container, as shown in Figures 2a-e.
- the placenta is delivered to the laboratory four to twenty-four hours following delivery.
- the placenta is preferably recovered after expulsion under aseptic conditions, and stored in an anticoagulant solution at a temperature of 5 to 25 °C (centigrade).
- Suitable anticoagulant solutions are well known in the art. For example, a solution of heparin or warfarin sodium can be used.
- the anticoagulant solution comprises a solution of heparin (1% w/w in 1 : 1000 solution).
- the drained placenta is preferably stored for no more than 36 hours before the embryonic-like stem cells are collected.
- the solution which is used to perfuse the placenta to remove residual cells can be the same solution used to perfuse and culture the placenta for the recovery of stem cells. Any of these perfusates maybe collected and used as a source of embryonic-like stem cells.
- the proximal umbilical cord is clamped, preferably within 4-5 cm (centimeter) of the insertion into the placental disc prior to cord blood recovery. In other embodiments, the proximal umbilical cord is clamped after cord blood recovery but prior to further processing of the placenta.
- a needle or cannula is used, with the aid of gravity, to drain cord blood from (i.e., exsanguinate) the placenta
- the placenta Boyse et al, U.S. Patent No. 5,192,553, issued March 9, 1993; Boyse et al, U.S. Patent No. 5,004,681, issued April 2, 1991; Anderson, U.S. Patent No. 5,372,581, entitled Method and apparatus for placental blood collection, issued December 13, 1994; Hessel et al, U.S. Patent No. 5,415,665, entitled Umbilical cord clamping, cutting, and blood collecting device and method, issued May 16, 1995).
- the needle or cannula is usually placed in the umbilical vein and the placenta is gently massaged to aid in draining cord blood from the placenta.
- the placenta is recovered from a patient by informed consent and a complete medical history of the patient prior to, during and after pregnancy is also taken and is associated with the placenta.
- These medical records can be used to coordinate subsequent use of the placenta or the stem cells harvested therefrom.
- the human placental stem cells can then easily be used for personalized medicine for the infant in question, the parents, siblings or other relatives.
- the human placental stem cells are more versatile than cord blood.
- the invention includes the addition of human placental stem cells produced by the exsanguinated, perfused and/or cultured placenta to cord blood from the same or different placenta and umbilical cord.
- the resulting cord blood will have an increased concentration/population of human stem cells and thereby is more useful for transplantation e.g. for bone marrow transplantations.
- the invention provides a method for recovery of stem or progenitor cells, including, but not limited to embryonic-like stem cells, from a placenta that is exsanguinated, i.e., completely drained of the cord blood remaining after birth and/or a conventional cord blood recovery procedure.
- the placenta is exsanguinated and perfused with a suitable aqueous perfusion fluid, such as an aqueous isotonic fluid in which an anticoagulant (e.g., heparin, warfarin sodium) is dissolved.
- aqueous isotonic fluids for perfusion are well known in the art, and include, e.g., a 0.9 N sodium chloride solution.
- the perfusion fluid preferably comprises the anticoagulant, such as heparin or warfarin sodium, at a concentration that is sufficient to prevent the formation of clots of any residual cord blood.
- a concentration of from 1 to 100 units of heparin is employed, preferably a concentration of 1 to 10 units of heparin per ml is employed.
- apoptosis inhibitors such as free radical scavengers, in particular oxygen free radical scavengers, can be used during and immediately after exsanguination and then these agents can be washed from the placenta.
- the isolated placenta may be stored under hypothermic conditions in order to prevent or inhibit apoptosis.
- the placenta is exsanguinated by passage of the perfusion fluid through either or both of the umbilical artery and umbilical vein, using a gravity flow into the placenta.
- the placenta is preferably oriented (e.g., suspended) in such a manner that the umbilical artery and umbilical vein are located at the highest point of the placenta.
- the umbilical artery and the umbilical vein are connected simultaneously, as shown in Figure 1, to a pipette that is connected via a flexible connector to a reservoir of the perfusion fluid.
- the perfusion fluid is passed into the umbilical vein and artery and collected in a suitable open vessel from the surface of the placenta that was attached to the uterus of the mother during gestation.
- the perfusion fluid may also be introduced through the umbilical cord opening and allowed to flow or perculate out of openings in the wall of the placenta which interfaced with the maternal uterine wall.
- the proximal umbilical cord is clamped during perfusion, and more preferably, is clamped within 4-5 cm (centimeter) of the cord's insertion into the placental disc.
- a sufficient amount of perfusion fluid is used that will result in removal of all residual cord blood and subsequent collection or recovery of placental cells, including but not limited to embryonic-like stem cells and progenitor cells, that remain in the placenta after removal of the cord blood. It has been observed that when perfusion fluid is first collected from a placenta during the exsanguination process, the fluid is colored with residual red blood cells of the cord blood. The perfusion fluid tends to become clearer as perfusion proceeds and the residual cord blood cells are washed out of the placenta.
- perfusion fluid Generally from 30 to 100 ml (milliliter) of perfusion fluid is adequate to exsanguinate the placenta and to recover an initial population of embryonic-like cells from the placenta, but more or less perfusion fluid may be used depending on the observed results.
- the embryonic-like stem cells are observed to migrate into the exsanguinated and perfused microcirculation of the placenta where, according to the methods of the invention, they are collected, preferably by washing into a collecting vessel by perfusion.
- Perfusing the isolated placenta not only serves to remove residual cord blood but also provide the placenta with the appropriate nutrients, including oxygen.
- the placenta may be cultivated and perfused with a similar solution which was used to remove the residual cord blood cells, preferably, without the addition of anticoagulant agents.
- the drained, exsanguinated placenta is cultured as a bioreactor, i.e., an ex vivo system for propagating cells or producing biological materials.
- the number of propagated cells or level of biological material produced in the placental bioreactor is maintained in a continuous state of balanced growth by periodically or continuously removing a portion of a culture medium or perfusion fluid that is introduced into the placental bioreactor, and from which the propagated cells or the produced biological materials may be recovered.
- Fresh medium or perfusion fluid is introduced at the same rate or in the same amount.
- the number and type of cells propagated may easily be monitored by measuring changes in morphology and cell surface markers using standard cell detection techniques such as flow cytometry, cell sorting, immunocytochemistry (e.g., staining with tissue specific or cell-marker specific antibodies) fluorescence activated cell sorting (FACS), magnetic activated cell sorting (MACS), by examination of the morphology of cells using light or confocal microscopy, or by measuring changes in gene expression using techniques well known in the art, such as PCR and gene expression profiling.
- standard cell detection techniques such as flow cytometry, cell sorting, immunocytochemistry (e.g., staining with tissue specific or cell-marker specific antibodies) fluorescence activated cell sorting (FACS), magnetic activated cell sorting (MACS), by examination of the morphology of cells using light or confocal microscopy, or by measuring changes in gene expression using techniques well known in the art, such as PCR and gene expression profiling.
- the cells may be sorted using a fluorescence activated cell sorter (FACS).
- Fluorescence activated cell sorting is a well-known method for separating particles, including cells, based on the fluorescent properties of the particles (Kamarch, 1987, Methods Enzymol, 151:150-165). Laser excitation of fluorescent moieties in the individual particles results in a small electrical charge allowing electromagnetic separation of positive and negative particles from a mixture.
- cell surface marker-specific antibodies or ligands are labeled with distinct fluorescent labels. Cells are processed through the cell sorter, allowing separation of cells based on their ability to bind to the antibodies used.
- FACS sorted particles may be directly deposited into individual wells of 96-well or 384- well plates to facilitate separation and cloning.
- magnetic beads can be used to separate cells.
- the cells may be sorted using a magnetic activated cell sorting (MACS) technique, a method for separating particles based on their ability to bind magnetic beads (0.5-100 ⁇ m diameter).
- a variety of useful modifications can be performed on the magnetic microspheres, including covalent addition of antibody which specifically recognizes a cell-solid phase surface molecule or hapten.
- a magnetic field is then applied, to physically manipulate the selected beads.
- the beads are then mixed with the cells to allow binding.
- Cells are then passed through a magnetic field to separate out cells having cell surface markers. These cells can then isolated and re-mixed with magnetic beads coupled to an antibody against additional cell surface markers.
- the cells are again passed through a magnetic field, isolating cells that bound both the antibodies.
- the placenta to be used as a bioreactor is exsanguinated and washed under sterile conditions so that any adherent coagulated and non-adherent cellular contaminants are removed.
- perfusate solution e.g., a normal saline solution such as phosphate buffered saline ("PBS")
- PBS phosphate buffered saline
- an anticoagulant e.g., heparin, warfarin sodium, coumarin, bishydroxycoumarin
- an antimicrobial agent e.g., ⁇ -mercaptoethanol (O.lmM)
- antibiotics such as streptomycin (e.g., at 40-100 ⁇ g/ml), penicillin (e.g., at 40U/ml), amphotericin B (e.g., at 0.5 ⁇ g/ml).
- the effluent perfusate comprises both circulated perfusate, which has flowed through the placental circulation, and extravasated perfusate, which exudes from or passes through the walls of the blood vessels into the surrounding tissues of the placenta.
- the effluent perfusate is collected, and preferably, both the circulated and extravasated perfusates are collected, preferably in a sterile receptacle. Alterations in the conditions in which the placenta is maintained and the nature of the perfusate can be made to modulate the volume and composition of the effluent perfusate.
- Cell types are then isolated from the collected perfusate by employing techniques known by those skilled in the art, such as for example, but not limited to density gradient centrifugation, magnet cell separation, flow cytometry, affinity cell separation or differential adhesion techniques.
- a placenta is placed in a sterile basin and washed with 500 ml of phosphate-buffered normal saline. The wash fluid is then discarded.
- the umbilical vein is then cannulated with a cannula, e.g., a TEFLON® or plastic cannula, that is connected to a sterile connection apparatus, such as sterile tubing.
- the sterile connection apparatus is connected to a perfusion manifold, as shown in Figure 3.
- the container containing the placenta is then covered and the placenta is maintained at room temperature (20-25 °C) for a desired period of time, preferably from 2 to 24 hours, and preferably, no longer than 48 hours.
- the placenta may be perfused continually, with equal volumes of perfusate introduced and effluent perfusate removed or collected.
- the placenta may be perfused periodically, e.g., at every 2 hours or at 4, 8, 12, and 24 hours, with a volume of perfusate, e.g., 100 ml of perfusate (sterile normal saline supplemented with or without 1000 u/1 heparin and/or EDTA and/or CPDA (creatine phosphate dextrose)).
- a volume of perfusate e.g., 100 ml of perfusate (sterile normal saline supplemented with or without 1000 u/1 heparin and/or EDTA and/or CPDA (creatine phosphate dextrose)
- perfusate e.g., 100 ml of perfusate (sterile normal saline supplemented with or without 1000 u/1 heparin and/or EDTA and/or CPDA (creatine phosphate dextrose)
- periodic perfusion preferably equal volumes of perfus
- the effluent perfusate that escapes the placenta is collected and processed to isolate embryonic-like stem cells, progenitor cells or other cells of interest.
- Various media may be used as perfusion fluid for culturing or cultivating the placenta, such as DMEM, F-12, M199, RPMI, Fisher's, Iscore's, McCoy's and combinations thereof, supplemented with fetal bovine serum (FBS), whole human serum (WHS), or human umbilical cord serum collected at the time of delivery of the placenta.
- FBS fetal bovine serum
- WLS whole human serum
- human umbilical cord serum collected at the time of delivery of the placenta.
- the same perfusion fluid used to exsanguinate the placenta of residual cord blood may be used to culture or cultivate the placenta, without the addition of anticoagulant agents.
- the embryonic-like stem cells are induced to propagate in the placenta bioreactor by introduction of nutrients, hormones, vitamins, growth factors, or any combination thereof, into the perfusion solution.
- Serum and other growth factors may be added to the propagation perfusion solution or medium.
- Growth factors are usually proteins and include, but are not limited to: cytokines, lymphokines, interferons, colony stimulating factors (CSF's), interferons, chemokines, and interleukins.
- growth factors include recombinant human hematopoietic growth factors including ligands, stem cell factors, thrombopoeitin (Tpo), granulocyte colony-stimulating factor (G- CSF), leukemia inhibitory factor, basic fibroblast growth factor, placenta derived growth factor and epidermal growth factor.
- the growth factors introduced into the perfusion solution can stimulate the propagation of undifferentiated embryonic-like stem cells, committed progenitor cells, or differentiated cells (e.g., differentiated hematopoietic cells).
- the growth factors can stimulate the production of biological materials and bioactive molecules including, but not limited to, immunoglobulins, hormones, enzymes or growth factors as previously described.
- the placenta is used as a bioreactor for propagating endogenous cells (i.e., cells that originate from the placenta), including but not limited to, various kinds of pluripotent and/or totipotent embryonic-like stem cells and lymphocytes.
- endogenous cells i.e., cells that originate from the placenta
- the placenta may be cultured for varying periods of time under sterile conditions by perfusion with perfusate solution as disclosed herein.
- the placenta is cultured for at least 12, 24, 36, or 48 hours, or for 3-5 days, 6-10 days, or for one to two weeks.
- the placenta is cultured for 48 hours.
- the cultured placenta should be "fed” periodically to remove the spent media, depopulate released cells, and add fresh media.
- the cultured placenta should be stored under sterile conditions to reduce the possibility of contamination, and maintained under intermittent and periodic pressurization to create conditions that maintain an adequate supply of nutrients to the cells of the placenta. It should be recognized that the perfusing and culturing of the placenta can be both automated and computerized for efficiency and increased capacity.
- the placenta is processed to remove all endogenous proliferating cells, such as embryonic-like stem cells, and to allow foreign (i.e., exogenous) cells to be introduced and propagated in the environment of the perfused placenta.
- the invention contemplates a large variety of stem or progenitor cells that can be cultured in the placental bioreactor, including, but not limited to, embryonic-like stem cells, mesenchymal stem cells, stromal cells, endothelial cells, hepatocytes, keratinocytes, and stem or progenitor cells for a particular cell type, tissue or organ, including but not limited to neurons, myelin, muscle, blood, bone marrow, skin, heart, connective tissue, lung, kidney, liver, and pancreas (e.g., pancreatic islet cells).
- embryonic-like stem cells including, but not limited to, embryonic-like stem cells, mesenchymal stem cells, stromal cells, endothelial cells, hepatocytes, keratinocytes, and stem or progenitor cells for a particular cell type, tissue or organ, including but not limited to neurons, myelin, muscle, blood, bone marrow, skin, heart, connective tissue, lung
- Sources of mesenchymal stem cells include bone marrow, embryonic yolk sac, placenta, umbilical cord, fetal and adolescent skin, and blood.
- Bone marrow cells may be obtained from iliac crest, femora, tibiae, spine, rib or other medullary spaces.
- the perfused placenta may be irradiated with electromagnetic, UN, X-ray, gamma- or beta-radiation to eradicate all remaining viable, endogenous cells.
- the foreign cells to be propagated are introduced into the irradiated placental bioreactor, for example, by perfusion.
- cells cultured in the placenta are isolated from the effluent perfusate using techniques known by those skilled in the art, such as, for example, density gradient centrifugation, magnet cell separation, flow cytometry, or other cell separation or sorting methods well known in the art, and sorted, for example, according to the scheme shown in Figure 4.
- cells collected from the placenta are recovered from the effluent perfusate by centrifugation at 5000 x g for 15 minutes at room temperature, which separates cells from contaminating debris and platelets.
- the cell pellets are resuspended in IMDM serum-free medium containing 2U/ml heparin and 2mM EDTA (GibcoBRL, NY).
- the total mononuclear cell fraction was isolated using Lymphoprep (Nycomed Pharma, Oslo, Norway) according to the manufacturer's recommended procedure and the mononuclear cell fraction was resuspended. Cells were counted using a hemocytometer. Viability was evaluated by trypan blue exclusion.
- Isolation of cells is achieved by "differential trypsinization," using a solution of 0.05% trypsin with 0.2% EDTA (Sigma, St. Louis MO). Differential trypsinization was possible because fibroblastoid cells detached from plastic surfaces within about five minutes whereas the other adherent populations required more than 20-30 minutes incubation. The detached fibroblastoid cells were harvested following trypsinization and trypsin neutralization, using Trypsin Neutralizing Solution (TNS, BioWhittaker). The cells were washed in H.DMEM and resuspended in MSCGM.
- the isolated placenta is perfused for a period of time without collecting the perfusate, such that the placenta may be perfused for 2, 4, 6, 8, 10, 12, 20 and 24 hours or even days before the perfusate is collected.
- cells cultured in the placenta bioreactor are isolated from the placenta by physically dissecting the cells away from the placenta.
- cells cultured in the placenta bioreactor are isolated from the placenta by dissociating the tissues of the placenta or a portion thereof, and recovering the cultured cells by art-known cell separation or sorting methods such as density gradient centrifugation, magnet cell separation, flow cytometry, etc.
- perfusion of the placenta and collection of effluent perfusate is repeated once or twice during the culturing of the placenta, until the number of recovered nucleated cells falls below 100 cells/ml.
- the perfusates are pooled and subjected to light centrifdgation to remove platelets, debris and de-nucleated cell membranes.
- the nucleated cells are then isolated by Ficoll-Hypaque density gradient centrifugation and after washing, resuspended in H.DMEM.
- aliquots of 5-10 x 10 6 cells are placed in each of several T-75 flasks and cultured with commercially available Mesenchymal Stem Cell Growth Medium (MSCGM) obtained from BioWhittaker, and placed in a tissue culture incubator (37°C, 5% CO 2 ). After 10 to 15 days, non-adherent cells are removed from the flasks by washing with PBS. The PBS is then replaced by MSCGM. Flasks are preferably examined daily for the presence of various adherent cell types and in particular, for identification and expansion of clusters of fibroblastoid cells. In other embodiments, the cells collected from the placenta are cryopreserved for use at a later time.
- MSCGM Mesenchymal Stem Cell Growth Medium
- cryopreservation of cells such as stem cells
- methods for cryopreservation using the methods of Boyse et al U.S. Patent No. 5,192,553, issued March 9, 1993
- Hu et al. WO 00/73421, published December 7, 2000.
- Embryonic-like stem cells obtained in accordance with the methods of the invention may include pluripotent cells, i.e., cells that have complete differentiation versatility, that are self-renewing, and can remain dormant or quiescent within tissue.
- the stem cells which may be obtained from the placenta include embryonic-like stem cells, multipotent cells, committed progenitor cells, and fibroblastoid cells.
- the first collection of blood from the placenta is referred to as cord blood which contains predominantly CD34+ and CD38+ hematopoietic progenitor cells.
- cord blood which contains predominantly CD34+ and CD38+ hematopoietic progenitor cells.
- high concentrations of CD34+ and CD38- hematopoietic progenitor cells may be isolated from the placenta, along with high concentrations of CD34- and CD38+ hematopoietic progenitor cells.
- high concentrations of CD34- and CD38- cells can be isolated from the placenta along with the aforementioned cells.
- the isolated perfused placenta of the invention provides a source of large quantities of stem cells enriched for CD34+ and CD38- stem cells and CD34- and CD38+ stem cells.
- the isolated placenta which has been perfused for twenty-four hours or more provides a source of large quantities of stem cells enriched for CD34- and CD38- stem cells.
- embryonic-like stem cells obtained by the methods of the invention are viable, quiescent, pluripotent stem cells that exist within a full-term human placenta and that can be recovered following successful birth and placental expulsion, resulting in the recovery of as many as one billion nucleated cells, which yield 50-100 million multipotent and pluripotent stem cells.
- the human placental stem cells provided by the placenta are surprisingly embryonic-like, for example, the presence of the following cell surface markers have been identified for these cells: SSEA3-, SSEA4-, OCT-4+ and ABC- ⁇ + .
- the embryonic-like stem cells of the invention are characterized by the presence of OCT-4+ and ABC-p+ cell surface markers.
- the invention encompasses stem cells which have not been isolated or otherwise obtained from an embryonic source but which can be identified by the following markers: SSAE3-, SSAE4-, OCT-4+ and ABC- ⁇ +.
- the human placental stem cells do not express MHC Class 2 antigens.
- the stem cells isolated from the placenta are homogenous, and sterile. Further, the stem cells are readily obtained in a form suitable for administration to humans, i.e., they are of pharmaceutical grade.
- Preferred embryonic-like stem cells obtained by the methods of the invention may be identified by the presence of the following cell surface markers: OCT-4+ and ABC-pt. Further, the invention encompasses embryonic stem cells having the following markers: CD 10+, CD38-, CD29+, CD34-, CD44+, CD45-, CD54+, CD90+, SH2+, SH3+, SH4+, SSEA3-, SSEA4-, OCT-4+, and ABC-p+.
- Such cell surface markers are routinely determined according to methods well known in the art, e.g. by flow cytometry, followed by washing and staining with an anti-cell surface marker antibody.
- cells may be washed in PBS and then double-stained with anti-CD34 phycoerythrin and anti-CD38 fluorescein isothiocyanate (Becton Dickinson, Mountain View, CA).
- cells cultured in the placenta bioreactor are identified and characterized by a colony forming unit assay, which is commonly known in the art, such as Mesen CultTM medium (stem cell Technologies, Inc., Vancouver British Columbia)
- embryonic-like stem cells obtained by the methods of the invention maybe induced to differentiate along specific cell lineages, including adipogenic, chondrogenic, osteogenic, hematopoietic, myogenic, vasogenic, neurogenic, and hepatogenic.
- embryonic-like stem cells obtained according to the methods of the invention are induced to differentiate for use in transplantation and ex vivo treatment protocols.
- embryonic-like stem cells obtained by the methods of the invention are induced to differentiate into a particular cell type and genetically engineered to provide a therapeutic gene product.
- embryonic-like stem cells obtained by the methods of the invention are incubated with a compound in vitro that induces it to differentiate, followed by direct transplantation of the differentiated cells to a subject.
- the invention encompasses methods of differentiating the human placental stem cells using standard culturing media.
- the invention encompasses hematopoietic cells, neuron cells, fibroblast cells, strand cells, mesenchymal cells and hepatic cells.
- Embryonic-like stem cells may also be further cultured after collection from the placenta using methods well known in the art, for example, by culturing on feeder cells, such as irradiated fibroblasts, obtained from the same placenta as the embryonic-like stem cells or from other human or nonhuman sources, or in conditioned media obtained from cultures of such feeder cells, in order to obtain continued long-term cultures of embryonic- like stem cells.
- the embryonic-like stem cells may also be expanded, either within the placenta before collection from the placental bioreactor or in vitro after recovery from the placenta.
- the embryonic-like stem cells to be expanded are exposed to, or cultured in the presence of, an agent that suppresses cellular differentiation.
- Such agents include, but are not limited to, human Delta- 1 and human Serrate-1 polypeptides (see, Sakano et al, U.S. Patent No. 6,337,387 entitled “Differentiation-suppressive polypeptide", issued January 8, 2002), leukemia inhibitory factor (LIF) and stem cell factor.
- LIF leukemia inhibitory factor
- stem cell factor stem cell factor
- the embryonic-like stem cells may be assessed for viability, proliferation potential, and longevity using standard techniques known in the art, such as trypan blue exclusion assay, fluorescein diacetate uptake assay, propidium iodide uptake assay (to assess viability); and thymidine uptake assay, MTT cell proliferation assay (to assess proliferation). Longevity may be determined by methods well known in the art, such as by determining the maximum number of population doubling in an extended culture.
- the differentiation of stem cells or progenitor cells that are cultivated in the exsanguinated, perfused and/or cultured placenta is modulated using an agent or pharmaceutical compositions comprising a dose and/or doses effective upon single or multiple administration, to exert an effect sufficient to inhibit, modulate and/or regulate the differentiation of a cell collected from the placenta.
- Agents that can induce stem or progenitor cell differentiation include, but are not limited to, Ca 2+ , EGF, aFGF, bFGF, PDGF, keratinocyte growth factor (KGF), TGF- ⁇ , cytokines (e.g., IL-l ⁇ , IL-l ⁇ , IFN- ⁇ , TFN), retinoic acid, transferrin, hormones (e.g., androgen, estrogen, insulin, prolactin, triiodothyronine, hydrocortisone, dexamethasone), sodium butyrate, TPA, DMSO, NMF, DMF, matrix elements (e.g., collagen, laminin, heparan sulfate, MatrigelTM), or combinations thereof.
- KGF keratinocyte growth factor
- TGF- ⁇ cytokines
- cytokines e.g., IL-l ⁇ , IL-l ⁇ , IFN- ⁇ , TFN
- transferrin e
- Agents that suppress cellular differentiation include, but are not limited to, human Delta-1 and human Serrate-1 polypeptides (see, Sakano et al, U.S. Patent No. 6,337,387 entitled “Differentiation-suppressive polypeptide", issued January 8, 2002), leukemia inhibitory factor (LIF), and stem cell factor.
- human Delta-1 and human Serrate-1 polypeptides see, Sakano et al, U.S. Patent No. 6,337,387 entitled “Differentiation-suppressive polypeptide”, issued January 8, 2002
- LIF leukemia inhibitory factor
- stem cell factor stem cell factor
- the agent used to modulate differentiation can be introduced into the placental bioreactor to induce differentiation of the cells being cultured in the placenta.
- the cells cultured in the placenta are stimulated to produce bioactive molecules, such as immunoglobulins, hormones, enzymes.
- the cells cultured in the placenta are stimulated to proliferate, for example, by administration of erythropoietin, cytokines, lymphokines, interferons, colony stimulating factors (CSF's), interferons, chemokines, interleukins, recombinant human hematopoietic growth factors including ligands, stem cell factors, thrombopoeitin (Tpo), interleukins, and granulocyte colony-stimulating factor (G-CSF) or other growth factors.
- CSF's colony stimulating factors
- chemokines chemokines
- interleukins recombinant human hematopoietic growth factors including ligands, stem cell factors, thrombopoeitin (Tpo), interleukins, and granulocyte colony-stimulating factor (G-CSF) or other growth factors.
- G-CSF granulocyte colony-stimulating factor
- cells cultured in the placenta are genetically engineered either prior to, or after collection from, the placenta, using, for example, a viral vector such as an adenoviral or retroviral vector, or by using mechanical means such as liposomal or chemical mediated uptake of the DNA.
- a viral vector such as an adenoviral or retroviral vector
- mechanical means such as liposomal or chemical mediated uptake of the DNA.
- a vector containing a transgene can be introduced into a cell of interest by methods well known in the art, e.g., transfection, transformation, transduction, electroporation, infection, microinjection, cell fusion, DEAE dextran, calcium phosphate precipitation, liposomes, LIPOFECTINTM, lysosome fusion, synthetic cationic lipids, use of a gene gun or a DNA vector transporter, such that the transgene is transmitted to daughter cells, e.g., the daughter embryonic-like stem cells or progenitor cells produced by the division of an embryonic-like stem cell.
- daughter cells e.g., the daughter embryonic-like stem cells or progenitor cells produced by the division of an embryonic-like stem cell.
- the transgene is introduced using any technique, so long as it is not destructive to the cell's nuclear membrane or other existing cellular or genetic structures.
- the transgene is inserted into the nucleic genetic material by microinjection. Microinjection of cells and cellular structures is commonly known and practiced in the art. For stable transfection of cultured mammalian cells, such as cells culture in a placenta, only a small fraction of cells may integrate the foreign DNA into their genome. The efficiency of integration depends upon the vector and transfection technique used.
- a gene that encodes a selectable marker is generally introduced into the host embryonic-like stem cell along with the gene sequence of interest.
- selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate.
- Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).
- drug selection e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die.
- Such methods are particularly useful in methods involving homologous recombination in mammalian cells (e.g., in embryonic-like stem cells) prior to introduction or transplantation of the recombinant cells into a subject or patient.
- a number of selection systems may be used to select transformed host embryonic- like cells.
- the vector may contain certain detectable or selectable markers.
- Other methods of selection include but are not limited to selecting for another marker such as: the herpes simplex virus thymidine kinase (Wigler et al, 1977, Cell 11 : 223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska and Szybalski, 1962, Proc. Natl. Acad. Sci.
- adenine phosphoribosyltransferase genes can be employed in tk-, hgprt- or aprt- cells, respectively.
- antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al, 1980, Proc. Natl. Acad. Sci. USA 77: 3567; O'Hare et al, 1981, Proc. Natl. Acad. Sci. USA 78: 1527); gpt, which confers resistance to mycophenolic acid (Mulligan and Berg, 1981, Proc.
- the transgene may integrate into the genome of the cell of interest, preferably by random integration.
- the transgene may integrate by a directed method, e.g., by directed homologous recombination (i.e., "knock-in” or "knock-out” of a gene of interest in the genome of cell of interest), Chappel, U.S. Patent No. 5,272,071; and PCT publication No. WO 91/06667, published May 16, 1991; U.S. Patent 5,464,764; Capecchi et al, issued November 7, 1995; U.S. Patent 5,627,059, Capecchi et al. issued, May 6, 1997; U.S. Patent 5,487,992, Capecchi et al, issued January 30, 1996).
- the construct will comprise at least a portion of a gene of interest with a desired genetic modification, and will include regions of homology to the target locus, i.e., the endogenous copy of the targeted gene in the host's genome.
- DNA constructs for random integration in contrast to those used for homologous recombination, need not include regions of homology to mediate recombination. Markers can be included in the targeting construct or random construct for performing positive and negative selection for insertion of the transgene.
- a homologous recombination vector is prepared in which a gene of interest is flanked at its 5' and 3' ends by gene sequences that are endogenous to the genome of the targeted cell, to allow for homologous recombination to occur between the gene of interest carried by the vector and the endogenous gene in the genome of the targeted cell.
- the additional flanking nucleic acid sequences are of sufficient length for successful homologous recombination with the endogenous gene in the genome of the targeted cell.
- flanking DNA typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector.
- Methods for constructing homologous recombination vectors and homologous recombinant animals from recombinant stem cells are commonly known in the art (see, e.g., Thomas and Capecchi, 1987, Cell 51: 503; Bradley, 1991, Curr. Opin. Bio/Technol. 2: 823- 29; and PCT Publication Nos. WO 90/11354, WO 91/01140, and WO 93/04169.
- the genome of an exogenous cell cultured in the placenta according to the methods of the invention is a target of gene targeting via homologous recombination or via random integration.
- the methods of Bonadio et al. are used to introduce nucleic acids into a cell of interest, such as a stem cell, progenitor cell or exogenous cell cultured in the placenta, e.g., bone progenitor cells.
- Exsanguinated and/or cultured placental cells can be used as a bioreactor for the cultivation of cells, tissues, and organs.
- the placental mesoderm provides an ideal stromal environment, including an abundance of small molecules and growth factors, lipopolysaccharides, and extracellular matrix proteins, necessary for organogenesis and tissue neogenesis.
- the invention provides a method of utilizing the isolated perfused placenta as a bioreactor for the propagation of exogenous cells.
- the invention relates to an isolated placenta which contains a cell not derived from the placenta, wherein the engraftment of said cell into the placenta may stimulate the placenta to produce embryonic-like stem cells, or wherein the engrafted cell produces signals, such as cytokines and growth factors, which may stimulate the placenta to produce stem cells.
- the placenta may be engrafted with cells not placental in origin obtained from the parents, siblings or other blood relatives of the infant associated with the placenta.
- the isolated placenta may be engrafted with cells not placental in origin obtained from an individual whom is not the infant, nor related to the infant.
- the cells, tissues, organoids and organs, which are propagated and cultivated in the placenta may be transplanted into the infant associated with the placenta, the parents, siblings or other blood relatives of said infant or into an individual not related to the infant.
- the placenta can be populated with any particular cell type and used as a bioreactor for ex vivo cultivation of cells, tissues or organs. Such cells, tissue or organ cultures may be harvested used in transplantation and ex vivo treatment protocols.
- the placenta is processed to remove all endogenous cells and to allow foreign (i.e., exogenous) cells to be introduced and propagated in the environment of the perfused placenta. Methods for removal of the endogenous cells are well-known in the art.
- the perfused placenta is irradiated with electromagnetic, UN, X-ray, gamma- or beta-radiation to eradicate all remaining viable, endogenous cells, h one embodiment, sub-lethal exposure to radiations e.g., 500 to 1500 CG ⁇ can be used to preserve the placenta but eradicate undesired cells.
- sub-lethal exposure to radiations e.g., 500 to 1500 CG ⁇
- the foreign cells of interest to be propagated in the irradiated placental bioreactor are then introduced, for example, by vascular perfusion or direct intra-parenchymal injection.
- the bioreactor may be used to produce and propagate novel chimeric cells, tissues, or organs.
- Such chimeras may be created using placental cells and one or more additional cell types as starting materials in a bioreactor. The interaction, or "cross-talk" between the different cell types can induce expression patterns distinct from either of the starting cell types.
- an autologous chimera is generated by propagating a patient's autologous placental cells in a bioreactor with another cell type derived from the same patient
- a heterologous chimera may be generated by addition of a patient's cells, i.e., blood cells, to a bioreactor having heterologous placental cells.
- the placental cells may be derived from a patient, and a second cell type from a second patient. Chimeric cells are then recovered having a different phenotypic and/or genetic characteristics from either of the starting cells.
- the heterologous cells are of the same haplotype, and the chimeric cells are reintroduced into the patient.
- the bioreactor may be used for enhanced growth of a particular cell type, whether native or synthetic in origin, or for the production of a cell-type specific product.
- the placental bioreactor may be used to stimulate pancreatic islet cells to produce insulin.
- the bioreactor is particularly advantageous for production of therapeutic mammalian proteins, whose therapeutic efficacy can be dependent upon proper post-translational modification.
- the bioreactor is useful for the production of therapeutic proteins, growth factors, cytokines, and other natural or recombinant therapeutic molecules, such as but not limited to, erythropoietin, interleukins, and interferons.
- the bioreactor may be used to propagate genetically engineered cells to provide a therapeutic gene product, and employed for large-scale production of the recombinant product.
- the reactor may be used to enhance antibody production.
- the placenta may be populated with antibody- producing cells, such as hybridomas, which produce a specific monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen.
- Hybridomas may be obtained by any technique, including, but not limited to, the hybridoma technique of Kohler and Milstein (1975, Nature 256, 495-497; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al, 1983, Immunology Today 4, 72; Cole et al, 1983, Proc. Natl. Acad. Sci.
- the mAb-producing hybridomas may be cultivated in the bioreactor to produce high titers of mAbs.
- the bioreactor may be used to generate antibodies specific for a particular cell-type, which may then be used identify the unknown antigen.
- antibodies may be generated against an unknown tumor-specific antigen in a cancer patient by culturing a whole blood specimen from a cancer patient, expanding the cells in a bioreactor, and then screened for antibodies that specifically react against a patient's tumor cells.
- the bioreactor may be used to produce viruses in culture and for screening for antiviral agents in culture. This method is of particular interest for those viruses, such as parvovirus and human immunodeficiency virus, which are difficult to propagate in cell culture conditions.
- the bioreactor may also be used as a support for screening for therapeutic molecules which modulate the activity of a particular cell type, such as the activity or expression of a gene product of interest or the activation of a signal transduction pathway, hi this embodiment, a cell type of interest may be cultured and expanded in the bioreactor.
- the cell may be naturally occurring cell, or a cell engineered to express a recombinant gene product.
- the bioreactor is then be contacted with candidate therapeutic molecules, such as small molecules, nonpeptides, antibodies, etc., or libraries of such candidate therapeutic molecules.
- candidate therapeutic molecules such as small molecules, nonpeptides, antibodies, etc., or libraries of such candidate therapeutic molecules.
- the cells are then analyzed for a change in a desired activity in the presence or absence of the candidate therapeutic molecule.
- such desired activity might be an increase or decrease in growth rate, and change in gene expression, or a change in binding or uptake of the candidate therapeutic molecule.
- methods are likely to be particularly convenient and/or useful for screening test agents. These include, but are not limited to, methods which measure binding of a compound, methods which measure a change in the ability cells to interact with an antibody or ligand, and methods which measure the activity or expression of "reporter" protein, that is, an enzyme or other detectable or selectable protein, which has been placed under the control of a control region of interest.
- reporter that is, an enzyme or other detectable or selectable protein, which has been placed under the control of a control region of interest.
- both naturally occurring and/or synthetic compounds e.g., libraries of small molecules or peptides
- the screening assays can be used to identify compounds and compositions including peptides and organic, non-protein molecules that modulate a cell-type specific activity.
- Recombinant, synthetic, and otherwise exogenous compounds may have binding capacity and, therefore, may be candidates for pharmaceutical agents.
- the proteins and compounds include endogenous cellular components which interact with the identified genes and proteins jn vivo. Such endogenous components may provide new targets for pharmaceutical and therapeutic interventions.
- the placenta is used as a bioreactor for propagating endogenous cells (i.e., cells that originate from the placenta), including but not limited to, various kinds of pluripotent and/or totipotent embryonic-like stem cells and lymphocytes.
- the placenta is incubated for varying periods of time with perfusate solution as disclosed herein.
- perfusate solution as disclosed herein.
- Such endogenous cells of placental origin may be transformed to recombinantly express a gene of interest, to express mutations, and/or may be engineered to delete a genetic locus, using "knock out" technology.
- an endogenous target gene may be deleted by inactivating or "knocking out” the target gene or its promoter using targeted homologous recombination (e.g., see Smithies, et al., 1985, Nature 317, 230-234; Thomas & Capecchi, 1987, Cell 51, 503-512; Thompson, et al., 1989, Cell 5, 313-321; each of which is incorporated by reference herein in its entirety).
- targeted homologous recombination e.g., see Smithies, et al., 1985, Nature 317, 230-234; Thomas & Capecchi, 1987, Cell 51, 503-512; Thompson, et al., 1989, Cell 5, 313-321; each of which is incorporated by reference herein in its entirety).
- a mutant, non-functional target gene flanked by DNA homologous to the endogenous target gene (either the coding regions or regulatory regions of the target gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express the target gene in vivo. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the target gene.
- Such approaches maybe used to remove, replace, or alter gene expression of interest in cells, tissue, and/or organs. This approach may be used to alter the phenotype of a cell, tissue, or organ, which may then be introduced into a human subject.
- a placenta cell may be induced to differentiate into a particular cell type, either ex vivo or in vivo.
- pluripotent embryonic-like stem cells maybe injected into a damaged organ, and for organ neo genesis and repair of injury in vivo.
- Such injury may be due to such conditions and disorders including, but not limited to, myocardial infarction, seizure disorder, multiple sclerosis, stroke, hypotension, cardiac arrest, ischemia, inflammation, age-related loss of cognitive function, radiation damage, cerebral palsy, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Leigh disease, AIDS dementia, memory loss, amyotrophic lateral sclerosis, ischemic renal disease, brain or spinal cord trauma, heart-lung bypass, glaucoma, retinal ischemia, or retinal trauma.
- myocardial infarction seizure disorder
- multiple sclerosis stroke
- hypotension cardiac arrest
- ischemia inflammation
- age-related loss of cognitive function radiation damage
- cerebral palsy neurodegenerative disease
- Alzheimer's disease Parkinson's disease
- Leigh disease Leigh disease
- AIDS dementia memory loss
- amyotrophic lateral sclerosis ischemic renal disease
- brain or spinal cord trauma heart-lung bypass
- glaucoma glaucoma
- the embryonic-like stem cells isolated from the placenta may be used, in specific embodiments, in autologous or heterologous enzyme replacement therapy to treat specific diseases or conditions, including, but not limited to lysosomal storage diseases, such as Tay- Sachs, Niemann-Pick, Fabry's, Gaucher's, Hunter's, and Hurler's syndromes, as well as other gangliosidoses, mucopolysaccharidoses, and glycogenoses.
- lysosomal storage diseases such as Tay- Sachs, Niemann-Pick, Fabry's, Gaucher's, Hunter's, and Hurler's syndromes, as well as other gangliosidoses, mucopolysaccharidoses, and glycogenoses.
- the cells may be used as autologous or heterologous transgene carriers in gene therapy to correct inborn errors of metabolism, adrenoleukodystrophy, cystic fibrosis, glycogen storage disease, hypothyroidism, sickle cell anemia, Pearson syndrome, Pompe's disease, phenylketonuria (PKU), porphyrias, maple syrup urine disease, homocystinuria, mucoplysaccharide nosis, chronic granulomatous disease and tyrosinemia and Tay-Sachs disease or to treat cancer, tumors or other pathological conditions.
- adrenoleukodystrophy cystic fibrosis
- glycogen storage disease hypothyroidism
- sickle cell anemia Pearson syndrome
- Pompe's disease phenylketonuria
- porphyrias maple syrup urine disease
- homocystinuria mucoplysaccharide nosis
- the cells may be used in autologous or heterologous tissue regeneration or replacement therapies or protocols, including, but not limited to treatment of corneal epithelial defects, cartilage repair, facial dermabrasion, mucosal membranes, tympanic membranes, intestinal linings, neurological structures (e.g., retina, auditory neurons in basilar membrane, olfactory neurons in olfactory epithelium), burn and wound repair for traumatic injuries of the skin, or for reconstruction of other damaged or diseased organs or tissues.
- the large numbers of embryonic-like stem cells and/or progenitor obtained using the methods of the invention would, in certain embodiments, reduce the need for large bone marrow donations.
- cells from a small bone marrow donation e.g., 7-10 ml
- stem cells and progenitor cells normally circulate in the blood stream.
- exogenous stem cells or exogenous progenitor cells are collected by pheresis, a procedure in which blood is withdrawn, one or more components are selectively removed, and the remainder of the blood is reinfused into the donor.
- the exogenous cells recovered by pheresis are expanded by propagation in a placental bioreactor, thus eliminating the need for bone marrow donation entirely.
- expansion of exogenous cells in a placental bioreactor is used as a supplemental treatment in addition to chemotherapy.
- Most chemotherapy agents used to target and destroy cancer cells act by killing all proliferating cells, i.e., cells going through cell division. Since bone marrow is one of the most actively proliferating tissues in the body, hematopoietic stem cells are frequently damaged or destroyed by chemotherapy agents and in consequence, blood cell production is diminishes or ceases.
- Chemotherapy must be terminated at intervals to allow the patient's hematopoietic system to replenish the blood cell supply before resuming chemotherapy.
- the embryonic-like stem cells, progenitor cells, foreign cells, or engineered cells obtained from a placenta according to the methods of the invention can be used in the manufacture of a tissue or organ in vivo.
- the methods of the invention encompass using cells obtained from the placenta, e.g., embryonic-like stem cells, progenitor cells, or foreign stem or progenitor cells, to seed a matrix and to be cultured under the appropriate conditions to allow the cells to differentiate and populate the matrix.
- the tissues and organs obtained by the methods of the invention may be used for a variety of purposes, including research and therapeutic purposes. 5.5 USES OF EMBRYONIC-LIKE STEM CELLS
- the embryonic-like stem cells of the invention can be used for a wide variety of therapeutic protocols in which a tissue or organ of the body is augmented, repaired or replaced by the engraftment, transplantation or infusion of a desired cell population, such as a stem cell or progenitor cell population.
- the embryonic-like stem cells of the invention can be used to replace or augment existing tissues, to introduce new or altered tissues, or to join together biological tissues or structures.
- the embryonic-like stem cells of the invention can also be substituted for embryonic stem cells in therapeutic protocols in which embryonic stem cells would be typically be used.
- embryonic-like stem cells and other stem cells from the placenta may be used as autologous and allogenic, including matched and mismatched HLA type hematopoietic transplants.
- embryonic-like stem cells as allogenic hematopoietic transplants it may be necessary to treat the host to reduce immuno logical rejection of the donor cells, such as those described in U.S. Patent No. 5,800,539, issued September 1, 1998; and U.S. Patent No. 5,806,529, issued September 15, 1998, both of which are incorporated herein by reference.
- embryonic-like stem cells of the invention can be used in therapeutic transplantation protocols, e.g., to augment or replace stem or progenitor cells of the liver, pancreas, kidney, lung, nervous system, muscular system, bone, bone marrow, thymus, spleen, mucosal tissue, gonads, or hair.
- therapeutic transplantation protocols e.g., to augment or replace stem or progenitor cells of the liver, pancreas, kidney, lung, nervous system, muscular system, bone, bone marrow, thymus, spleen, mucosal tissue, gonads, or hair.
- Embryonic-like stem cells maybe used instead of specific classes of progenitor cells (e.g., chondrocytes, hepatocytes, hematopoietic cells, pancreatic parenchymal cells, neuroblasts, muscle progenitor cells, etc.) in therapeutic or research protocols in which progenitor cells would typically be used.
- Embryonic-like stem cells of the invention can be used for augmentation, repair or replacement of cartilage, tendon, or ligaments.
- prostheses e.g., hip prostheses
- joints e.g., knee
- Cartilage tissue constructs can also be employed in major reconstructive surgery for different types of joints (for protocols, see e.g., Resnick, D., and Niwayama, G., eds., 1988, Diagnosis of Bone and Joint Disorders, 2d ed., W. B. Saunders Co.).
- the embryonic-like stem cells of the invention can be used to repair damage of tissues and organs resulting from disease.
- a patient can be administered embryonic-like stem cells to regenerate or restore tissues or organs which have been damaged as a consequence of disease, e.g., enhance immune system following chemotherapy or radiation, repair heart tissue following myocardial infarction.
- the embryonic-like stem cells of the invention can be used to augment or replace bone marrow cells in bone marrow transplantation.
- Human autologous and allogenic bone marrow transplantation are currently used as therapies for diseases such as leukemia, lymphoma and other life-threatening disorders.
- the drawback of these procedures is that a large amount of donor bone marrow must be removed to insure that there is enough cells for engraftment. ⁇
- the embryonic-like stem cells collected according to the methods of the invention can provide stem cells and progenitor cells that would reduce the need for large bone marrow donation. It would also be, according to the methods of the invention, to obtain a small marrow donation and then expand the number of stem cells and progenitor cells culturing and expanding in the placenta before infusion or transplantation into a recipient.
- the embryonic-like stem cells isolated from the placenta may be used, in specific embodiments, in autologous or heterologous enzyme replacement therapy to treat specific diseases or conditions, including, but not limited to lysosomal storage diseases, such as Tay- Sachs, Niemann-Pick, Fabry's, Gaucher's, Hunter's, Hurler's syndromes, as well as other gangliosidoses, mucopolysaccharidoses, and glycogenoses.
- lysosomal storage diseases such as Tay- Sachs, Niemann-Pick, Fabry's, Gaucher's, Hunter's, Hurler's syndromes, as well as other gangliosidoses, mucopolysaccharidoses, and glycogenoses.
- the cells may be used as autologous or heterologous transgene carriers in gene therapy to correct inborn errors of metabolism such as adrenoleukodystrophy, cystic fibrosis, glycogen storage disease, hypothyroidism, sickle cell anemia, Pearson syndrome, Pompe's disease, phenylketonuria (PKU), and Tay-Sachs disease, porphyrias, maple syrup urine disease, homocystinuria, mucopolypsaccharide nosis, chronic granulomatous disease, and tyrosinemia. or to treat cancer, tumors or other pathological conditions.
- the cells may be used in autologous or heterologous tissue regeneration or replacement therapies or protocols, including, but not limited to treatment of corneal epithelial defects, cartilage repair, facial dermabrasion, mucosal membranes, tympanic membranes, intestinal linings, neurological structures (e.g., retina, auditory neurons in basilar membrane, olfactory neurons in olfactory epithelium), burn and wound repair for traumatic injuries of the skin, scalp (hair) transplantation, or for reconstruction of other damaged or diseased organs or tissues.
- therapies or protocols including, but not limited to treatment of corneal epithelial defects, cartilage repair, facial dermabrasion, mucosal membranes, tympanic membranes, intestinal linings, neurological structures (e.g., retina, auditory neurons in basilar membrane, olfactory neurons in olfactory epithelium), burn and wound repair for traumatic injuries of the skin, scalp (hair) transplantation, or for reconstruction of other damaged or diseased organs or
- the large numbers of embryonic-like stem cells and/or progenitor obtained using the methods of the invention would, in certain embodiments, reduce the need for large bone marrow donations.
- Approximately 1 x 10 8 to 2 x 10 8 bone marrow mononuclear cells per kilogram of patient weight must be infused for engraftment in a bone marrow transplantation (i.e., about 70 ml of marrow for a 70 kg donor).
- 70 ml requires an intensive donation and significant loss of blood in the donation process.
- cells from a small bone marrow donation e.g., 7-10 ml
- the embryonic-like stem cells can be used in a supplemental treatment in addition to chemotherapy.
- Most chemotherapy agents used to target and destroy cancer cells act by killing all proliferating cells, i.e., cells going through cell division. Since bone marrow is one of the most actively proliferating tissues in the body, hematopoietic stem cells are frequently damaged or destroyed by chemotherapy agents and in consequence, blood cell production is diminishes or ceases.
- Chemotherapy must be terminated at intervals to allow the patient's hematopoietic system to replenish the blood cell supply before resuming chemotherapy. It may take a month or more for the formerly quiescent stem cells to proliferate and increase the white blood cell count to acceptable levels so that chemotherapy may resume (when again, the bone marrow stem cells are destroyed).
- the cancer has time to grow and possibly become more resistant to the chemotherapy drugs due to natural selection. Therefore, the longer chemotherapy is given and the shorter the duration between treatments, the greater the odds of successfully killing the cancer.
- embryonic-like stem cells or progenitor cells collected according to the methods of the invention could be introduced into the patient. Such treatment would reduce the time the patient would exhibit a low blood cell count, and would therefore permit earlier resumption of the chemotherapy treatment.
- the human placental stem cells can be used to treat or prevent genetic diseases such as chronic granulomatous disease.
- the present invention encompasses pharmaceutical compositions comprising a dose and/or doses effective upon single or multiple administration, prior to or following transplantation of conditioned or unconditioned human progenitor stem cells, exerting effect sufficient to inhibit, modulate and/or regulate the differentiation of human pluripotent and multipotent progenitor stem cells of placental origin into mesodermal and/or hematopoietic lineage cells.
- the embryonic-like stem cells of the invention may be formulated as an injectable (e.g., PCT WO 96/39101, incorporated herein by reference in its entirety).
- the cells and tissues of the present invention may be formulated using polymerizable or cross linking hydrogels as described in 5 U.S. Patent Nos. 5,709,854; 5,516,532; 5,654,381; each of which is incorporated by reference in their entirety.
- This example describes the analysis of the cell types recovered from the effluent perfusate of a placenta cultured according to the methods of the invention.
- phosphate buffered saline solution PBS
- a 10 ml portion was collected and centrifuged for 25 minutes at 3000 rpm 15 (revolutions per minute).
- the effluent was divided into four tubes and placed in an ice bath.
- 2.5 ml of a 1% fetal calf serum (FCS) solution in PBS was added and the tubes were centrifuged (140 minutes x 10 g (acceleration due to gravity)).
- FCS 1% fetal calf serum
- the pellet was resuspended in 5 ml of 1% FCS and two tubes were combined.
- the total mononucleocytes were calculated by adding the total lymphocytes and the total monocytes, and then multiplying 20 the result by the total cell suspension volume.
- the following table discloses the types of cells obtained by perfusion of a cultured placenta according to the methods described hereinabove.
- Total cell number of PP after Ficoll was 5.3 X 10 8 and number of CB before processing is 6.3 X 10 8 .
- Lym% indicates percent of lymphocytes; M1D% indicates percent of midrange white blood cells; and GRA%> indicates percent of granulocytes.
- the following example describes an analysis of cells obtained by perfusion and incubation of placenta according to the methods of the invention.
- Placenta donors were recruited from expectant mothers that enrolled in private umbilical cord blood banking programs and provided informed consent permitting the use of the exsanguinated placenta following recovery of cord blood for research purposes.
- Donor data may be confidential.
- These donors also permitted use of blinded data generated from the normal processing of their umbilical cord blood specimens for cryopreservation. This allowed comparison between the composition of the collected cord blood and the effluent perfusate recovered using the experimental method described below.
- placenta Following exsanguination of cord blood from the umbilical cord and placenta is stored at room temperature and delivered to the laboratory within four to twenty-four hour, according to the methods described hereinabove, the placenta was placed in a sterile, insulated container at room temperature and delivered to the laboratory within 4 hours of birth. Placentas were discarded if, on inspection, they had evidence of physical damage such as fragmentation of the organ or avulsion of umbilical vessels. Placentas were maintained at room temperature (23 ⁇ 2°C) or refrigerated (4°C) in sterile containers for 2 to 20 hours. Periodically, the placentas were immersed and washed in sterile saline at 25 ⁇ 3 °C to remove any visible surface blood or debris.
- the umbilical cord was transected approximately 5 cm from its insertion into the placenta and the umbilical vessels were cannulated with TEFLON® or polypropylene catheters connected to a sterile fluid path allowing bi-directional perfusion of the placenta and recovery of the effluent fluid.
- the methods described hereinabove enabled all aspects of placental conditioning, perfusion and effluent collection to be performed under controlled ambient atmospheric conditions as well as real-time monitoring of intravascular pressure and flow rates, core and perfusate temperatures and recovered effluent volumes.
- a range of conditioning protocols were evaluated over a 24-hour postpartum period, and the cellular composition of the effluent fluid was analyzed by flow cytometry, light microscopy and colony forming unit assays. 6.2.2. PLACENTAL CONDITIONING
- the donor placentas were processed at room temperature within 12 to 24 hours after delivery. Before processing, the membranes were removed and the maternal site washed clean of residual blood. The umbilical vessels were cannulated with catheters made from 20 gauge Butterfly needles use for blood sample collection.
- the donor placentas were maintained under varying conditions such as maintenance at 5-37° 5% CO 2 , pH 7.2 to 7.5, preferably pH 7.45, in an attempt to simulate and sustain a physiologically compatible environment for the proliferation and recruitment of residual embryonic-like stem cells.
- the cannula was flushed with IMDM serum-free medium (GibcoBRL, NY) containing 2U/ml heparin (Elkins-Sinn, NJ). Perfusion of the placenta continued at a rate of 50 ml per minute until approximately 150 ml of perfusate was collected.
- Placentas were then perfused with heparinized (2U/ml) Dulbecco's modified Eagle Medium (H.DMEM) at the rate of 15 ml/minute for 10 minutes and the perfusates were collected from the maternal sites within one hour and the nucleated cells counted. The perfusion and collection procedures were repeated once or twice until the number of recovered nucleated cells fell below 100/ml. The perfusates were pooled and subjected to light centrifugation to remove platelets, debris and de-nucleated cell membranes. The nucleated cells were then isolated by Ficoll-Hypaque density gradient centrifugation and after washing, resuspended in H.DMEM.
- H.DMEM heparinized (2U/ml) Dulbecco's modified Eagle Medium
- aliquots of 5- 10 x 10 6 cells were placed in each of several T-75 flasks and cultured with commercially available Mesenchymal Stem Cell Growth Medium (MSCGM) obtained from BioWhittaker, and placed in a tissue culture incubator (37°C, 5% CO 2 ). After 10 to 15 days, the non-adherent cells were removed by washing with PBS, which was then replaced by MSCGM. The flasks were examined daily for the presence of various adherent cell types and in particular, for identification and expansion of clusters of fibroblastoid cells.
- MSCGM Mesenchymal Stem Cell Growth Medium
- Cells were recovered from the perfusates by centrifugation at 5000 x g for 15 minutes at room temperature. This procedure served to separate cells from contaminating debris and platelets. The cell pellets were resuspended in IMDM serum-free medium containing 2U/ml heparin and 2mM EDTA (GibcoBRL, NY). The total mononuclear cell fraction was isolated using Lymphoprep (Nycomed Pharma, Oslo, Norway) according to the manufacturer's recommended procedure and the mononuclear cell fraction was resuspended. Cells were counted using a hemocytometer. Viability was evaluated by trypan blue exclusion.
- Isolation of mesenchymal cells was achieved by "differential trypsinization," using a solution of 0.05% trypsin with 0.2% EDTA (Sigma, St. Louis MO). Differential trypsinization was possible because fibroblastoid cells detached from plastic surfaces within about five minutes whereas the other adherent populations required more than 20-30 minutes incubation. The detached fibroblastoid cells were harvested following trypsinization and trypsin neutralization, using Trypsin Neutralizing Solution (TNS, BioWhittaker). The cells were washed in H.DMEM and resuspended in MSCGM.
- Flow cytometry was carried out using a Becton-Dickinson FACSCalibur instrument and FITC and PE labeled monoclonal antibodies (mAbs), selected on the basis of known markers for bone marrow-derived MSC (mesenchymal stem cells), were purchased from B.D. and Caltag laboratories (South San Francisco, CA.), and SH2, SH3 and SH4 antibody producing hybridomas were obtained from and reactivities of the mAbs in their cultured supernatants were detected by FITC or PE labeled F(ab)'2 goat anti-mouse antibodies. Lineage differentiation was carried out using commercially available induction and maintenance culture media (BioWhittaker), used as per manufacturer's instructions.
- BioWhittaker commercially available induction and maintenance culture media
- the placenta-derived embryonic-like stem cells in contrast to their earlier phase, adhered within hours, assumed characteristic fibroblastoid shape, and formed a growth pattern identical to the reference bone marrow-derived MSC.
- the loosely bound mononuclear cells were washed out and the cultures remained homogeneous and devoid of any visible non-fibroblastoid cell contaminants.
- CD-34, CD-38, and other stem cell-associated surface markers on early and late fraction purified mononuclear cells was assessed by flow cytometry. Recovered, sorted cells were washed in PBS and then double-stained with antiCD34 phycoerythrin and anti-CD38 fluorescein isothiocyanate (Becton Dickinson, Mountain View, CA).
- Cell isolation was achieved by using magnetic cell separation, such as for example, Auto Macs (Miltenyi).
- CD 34+ cell isolation is performed first.
- the above-composition is a perfusate that maybe used at a variety of temperatures to perfuse placenta. It should be noted that additional components such as antibiotics, anticoagulant and other growth factors may be used in the perfusate or culture media.
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02720974.1A EP1362095B1 (en) | 2001-02-14 | 2002-02-13 | Post-partum mammalian placenta, its use and placental stem cells therefrom |
MX2012001630A MX352687B (en) | 2001-02-14 | 2002-02-13 | Post-partum mammalian placenta, its use and placental stem cells therefrom. |
MX2013011498A MX348185B (en) | 2001-02-14 | 2002-02-13 | Post-partum mammalian placenta, its use and placental stem cells therefrom. |
IL15735002A IL157350A0 (en) | 2001-02-14 | 2002-02-13 | Post-partum mammalian placenta, its use and placental stem cells therefrom |
NZ527849A NZ527849A (en) | 2001-02-14 | 2002-02-13 | Post-partum mammalian placenta, its use and placental stem cells therefrom |
MXPA03007175A MXPA03007175A (en) | 2001-02-14 | 2002-02-13 | Post-partum mammalian placenta, its use and placental stem cells therefrom. |
CA2438153A CA2438153C (en) | 2001-02-14 | 2002-02-13 | Post-partum mammalian placenta, its use and placental stem cells therefrom |
KR1020097027197A KR101132545B1 (en) | 2001-02-14 | 2002-02-13 | Post-partum mammalian placenta, its use and placental stem cells therefrom |
KR1020037010671A KR100973615B1 (en) | 2001-02-14 | 2002-02-13 | Post-partum mammalian placenta, its use and placental stem cells therefrom |
JP2002565070A JP2004528021A (en) | 2001-02-14 | 2002-02-13 | Postpartum mammalian placenta, its use and placental stem cells derived therefrom |
AU2002251935A AU2002251935B2 (en) | 2001-02-14 | 2002-02-13 | Post-partum mammalian placenta, its use and placental stem cells therefrom |
ES02720974.1T ES2545899T3 (en) | 2001-02-14 | 2002-02-13 | Placenta post-partum of mammals, their use and placental stem cells thereof |
IL157350A IL157350A (en) | 2001-02-14 | 2003-08-12 | Post-partum mammalian placenta, its use and placental stem cells therefrom |
HK04101879.0A HK1059801A1 (en) | 2001-02-14 | 2004-03-15 | Post-partum mammalian placenta, its use and placental stem cells therefrom |
IL201916A IL201916A (en) | 2001-02-14 | 2009-11-04 | Human placental stem cells, characteristics, preparation and use thereof |
IL207024A IL207024A0 (en) | 2001-02-14 | 2010-07-15 | Post-partum mammaliand placental stem cells |
IL207025A IL207025A (en) | 2001-02-14 | 2010-07-15 | Post-partum mammalian placental stem cells and uses thereof for treating disorders |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26856001P | 2001-02-14 | 2001-02-14 | |
US60/268,560 | 2001-02-14 | ||
US10/004,942 | 2001-12-05 | ||
US10/004,942 US7045148B2 (en) | 2000-12-06 | 2001-12-05 | Method of collecting placental stem cells |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002064755A2 true WO2002064755A2 (en) | 2002-08-22 |
WO2002064755A3 WO2002064755A3 (en) | 2002-12-19 |
Family
ID=26673686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/004282 WO2002064755A2 (en) | 2001-02-14 | 2002-02-13 | Post-partum mammalian placenta, its use and placental stem cells therefrom |
Country Status (9)
Country | Link |
---|---|
US (3) | US20030032179A1 (en) |
EP (7) | EP1362095B1 (en) |
JP (1) | JP2004528021A (en) |
AU (1) | AU2002251935B2 (en) |
CA (3) | CA3046566A1 (en) |
IL (1) | IL157350A0 (en) |
MX (1) | MXPA03007175A (en) |
NZ (2) | NZ541541A (en) |
WO (1) | WO2002064755A2 (en) |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004047770A2 (en) * | 2002-11-26 | 2004-06-10 | Anthrogenesis Corporation | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
EP1482787A2 (en) * | 2002-02-13 | 2004-12-08 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
WO2005056026A1 (en) * | 2003-12-04 | 2005-06-23 | Regents Of The University Of Minnesota | Compositions and methods for the treatment of lysosomal storage disorders |
WO2005061695A1 (en) * | 2003-12-23 | 2005-07-07 | Carag Ag | Method for isolating cells from mammary secretion |
WO2005073366A1 (en) * | 2004-01-30 | 2005-08-11 | Lifecord Inc. | Method for isolating and culturing multipotent progenitor/stem cells from umbilical cord blood and method for inducing differentiation thereof |
WO2005097190A2 (en) | 2004-03-26 | 2005-10-20 | Celgene Corporation | Systems and methods for providing a stem cell bank |
EP1601248A2 (en) * | 2003-02-13 | 2005-12-07 | Anthrogenesis Corporation | Use of umbilical cord blood to treat individuals having a disease, disorder or condition |
WO2006015214A2 (en) * | 2004-07-29 | 2006-02-09 | Steenblock Research Institute, Inc. | Umbilical cord stem cell composition & method of treating neurological diseases |
EP1708757A1 (en) * | 2003-12-19 | 2006-10-11 | Viacell, Inc. | Use of human cord blood-derived pluripotent cells for the treatment of disease |
WO2007079185A2 (en) * | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Improved composition for collecting and preserving placental stem cells and methods of using the composition |
JP2007528702A (en) * | 2003-06-27 | 2007-10-18 | エチコン、インコーポレイテッド | Most postpartum cells derived from placental tissue and methods of making and using them. |
WO2007133030A1 (en) * | 2006-05-12 | 2007-11-22 | Seoul National University Industry Foundation | Multipotent adult stem cell derived from canine umbilical cord blood, placenta and canine fetus heart, method for preparing the same and cellular therapeutics containing the same |
WO2008060541A3 (en) * | 2006-11-13 | 2008-08-28 | Ethicon Inc | In vitro expansion of postpartum-derived cells using microcarriers |
KR100871984B1 (en) | 2006-04-12 | 2008-12-05 | 주식회사 알앤엘바이오 | Multipotent Stem Cell Derived from Placenta Tissue and Cellular Therapeutic Agents Comprising the Same |
EP2023717A2 (en) * | 2006-05-11 | 2009-02-18 | Naoko Takebe | Methods for collecting and using placenta cord blood stem cells |
WO2009061447A2 (en) * | 2007-11-07 | 2009-05-14 | Anthrogenesis Corporation | Treatment of premature birth complications |
EP2089510A2 (en) * | 2006-06-28 | 2009-08-19 | The University of Medicine and Dentistry of New Jersey | Amnion-derived stem cells and uses thereof |
WO2010026573A1 (en) * | 2008-09-02 | 2010-03-11 | Pluristem Ltd. | Methods of selection of cells for transplantation |
EP2186407A1 (en) | 2002-02-13 | 2010-05-19 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
US7875272B2 (en) | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
US7875273B2 (en) | 2004-12-23 | 2011-01-25 | Ethicon, Incorporated | Treatment of Parkinson's disease and related disorders using postpartum derived cells |
US7927587B2 (en) | 1999-08-05 | 2011-04-19 | Regents Of The University Of Minnesota | MAPC administration for the treatment of lysosomal storage disorders |
WO2011093732A1 (en) | 2010-01-26 | 2011-08-04 | Stem Cells Spin S.A. | Cell homogenate from stem cells derived from growing deer antlers, a method of obtaining it and its use |
US8071376B2 (en) | 2005-10-13 | 2011-12-06 | Anthrogenesis Corporation | Production of oligodendrocytes from placenta-derived stem cells |
US8529888B2 (en) | 2007-09-19 | 2013-09-10 | Pluristem Ltd. | Adherent cells from adipose or placenta tissues and use thereof in therapy |
US8673547B2 (en) | 2007-03-08 | 2014-03-18 | Hemacell Perfusion, Inc. | Method for isolation of afterbirth derived cells |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
WO2015051088A1 (en) * | 2013-10-03 | 2015-04-09 | Anthrogenesis Corporation | Therapy with cells from human placenta and hematopoietic cells |
US9005964B2 (en) | 2006-11-24 | 2015-04-14 | Regents Of The University Of Minnesota | Endodermal progenitor cells |
WO2015073800A2 (en) | 2013-11-15 | 2015-05-21 | Anthrogenesis Corporation | Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses |
US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
US9078898B2 (en) | 2005-12-29 | 2015-07-14 | Anthrogenesis Corporation | Placental stem cell populations |
US9085755B2 (en) | 2004-08-16 | 2015-07-21 | Cellresearch Corporation Pte Ltd. | Isolation, cultivation and uses of stem/progenitor cells |
EP2937415A1 (en) * | 2014-03-31 | 2015-10-28 | Sysmex Corporation | Method for obtaining differentiated cells and/or differentiated cell products from undifferentiated cell |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9175261B2 (en) | 2005-12-16 | 2015-11-03 | DePuy Synthes Products, Inc. | Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
US9339520B2 (en) | 2006-10-23 | 2016-05-17 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
EP3031909A1 (en) * | 2005-10-13 | 2016-06-15 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9611513B2 (en) | 2011-12-23 | 2017-04-04 | DePuy Synthes Products, Inc. | Detection of human umbilical cord tissue derived cells |
AU2014201181B2 (en) * | 2005-12-29 | 2017-07-20 | Celularity Inc. | Placental stem cell populations |
US9758762B2 (en) | 2008-09-02 | 2017-09-12 | Pluristem Ltd. | Perfusion bioreactor for culturing CD200—placenta adherent cells |
US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
US9943552B2 (en) | 2009-03-26 | 2018-04-17 | DePuy Synthes Products, Inc. | hUTC as therapy for Alzheimer's disease |
US9944900B2 (en) | 2006-01-18 | 2018-04-17 | Hemacell Perfusion | Pulsatile perfusion extraction method for non-embryonic pluripotent stem cells |
US10047345B2 (en) | 2012-02-13 | 2018-08-14 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells with FGF4 and nicotinamide |
US10104880B2 (en) | 2008-08-20 | 2018-10-23 | Celularity, Inc. | Cell composition and methods of making the same |
US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
EP3502233A1 (en) * | 2017-12-21 | 2019-06-26 | Institut National de la Sante et de la Recherche Medicale (INSERM) | System for studying ex-vivo transplacental transfer |
US10494607B2 (en) | 2007-02-12 | 2019-12-03 | Celularity, Inc. | CD34+,CD45−placental stem cell-enriched cell populations |
US10557116B2 (en) | 2008-12-19 | 2020-02-11 | DePuy Synthes Products, Inc. | Treatment of lung and pulmonary diseases and disorders |
US10722541B2 (en) | 2011-03-22 | 2020-07-28 | Pluristem Ltd. | Methods for treating radiation or chemical injury |
US10744164B2 (en) | 2003-06-27 | 2020-08-18 | DePuy Synthes Products, Inc. | Repair and regeneration of ocular tissue using postpartum-derived cells |
Families Citing this family (227)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2338405T3 (en) * | 1999-02-04 | 2010-05-07 | Pluristem Ltd. | METHOD AND APPARATUS FOR MAINTENANCE AND EXPASION OF HEMOPOYTIC MOTHER CELLS AND / OR PROGENITOR CELLS. |
US8609412B2 (en) * | 1999-08-05 | 2013-12-17 | Regents Of The University Of Minnesota | Mapc generation of lung tissue |
US10638734B2 (en) * | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
US7015037B1 (en) * | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
US20080152629A1 (en) * | 2000-12-06 | 2008-06-26 | James Edinger | Placental stem cell populations |
US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
IL156303A0 (en) | 2000-12-06 | 2004-01-04 | Robert J Hariri | Method of collecting placental stem cells |
EP1362095B1 (en) * | 2001-02-14 | 2015-05-27 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
KR101132545B1 (en) * | 2001-02-14 | 2012-04-02 | 안트로제네시스 코포레이션 | Post-partum mammalian placenta, its use and placental stem cells therefrom |
EP1367899A4 (en) * | 2001-02-14 | 2004-07-28 | Leo T Furcht | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
AU2007234581B2 (en) * | 2001-02-14 | 2012-02-02 | Celularity Inc. | Post-partum mammalian placenta, its use and placental stem cells therefrom |
US6942802B2 (en) * | 2001-04-13 | 2005-09-13 | Wyeth Holdings Corporation | Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography |
FR2825261B1 (en) * | 2001-06-01 | 2003-09-12 | Maco Pharma Sa | PLACENTAL BLOOD COLLECTION LINE COMPRISING A RINSING POCKET |
US20050148034A1 (en) * | 2002-04-12 | 2005-07-07 | Hariri Robert J. | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
EP1538913A2 (en) * | 2002-04-12 | 2005-06-15 | Celgene Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US20030235563A1 (en) * | 2002-04-19 | 2003-12-25 | Strom Stephen C. | Placental derived stem cells and uses thereof |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
CN1668733A (en) * | 2002-05-30 | 2005-09-14 | 细胞基因公司 | Methods of using JNK or MKK inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
WO2004050859A2 (en) | 2002-11-27 | 2004-06-17 | Regents Of The University Of Minnesota | Homologous recombination in multipotent adult progenitor cells |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
US8518390B2 (en) | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
US8491883B2 (en) * | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
AU2011226863B2 (en) * | 2003-06-27 | 2013-04-04 | Ethicon Incorporated | Regeneration and repair of neural tissue using postpartum-derived cells |
AU2011226961B2 (en) * | 2003-06-27 | 2012-06-14 | Ethicon Incorporated | Regeneration and repair of neural tissue using postpartum-derived cells |
ITRM20030376A1 (en) | 2003-07-31 | 2005-02-01 | Univ Roma | PROCEDURE FOR THE ISOLATION AND EXPANSION OF CARDIOC STAMIN CELLS FROM BIOPSIA. |
GB0321337D0 (en) * | 2003-09-11 | 2003-10-15 | Massone Mobile Advertising Sys | Method and system for distributing advertisements |
WO2005055929A2 (en) * | 2003-12-02 | 2005-06-23 | Celgene Corporation | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
US7534606B2 (en) * | 2004-01-12 | 2009-05-19 | National Health Research Institutes | Placental stem cell and methods thereof |
US20080004228A1 (en) * | 2004-03-09 | 2008-01-03 | Imre Berger | New Expression Tools for Multiprotein Applications |
CN101080486B (en) * | 2004-04-23 | 2012-05-16 | 佰欧益股份有限公司 | Multi-lineage progenitor cells |
US7622108B2 (en) * | 2004-04-23 | 2009-11-24 | Bioe, Inc. | Multi-lineage progenitor cells |
US8309070B2 (en) | 2004-05-17 | 2012-11-13 | Regents Of The University Of Minnesota | Use of umbilical cord blood stem cells to treat ischemic event |
US7147626B2 (en) * | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
US7909806B2 (en) * | 2004-09-23 | 2011-03-22 | Anthrogenesis Corporation | Cord blood and placenta collection kit |
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
US20060153815A1 (en) * | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
WO2006101548A2 (en) * | 2004-12-21 | 2006-09-28 | Ethicon, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same |
US20060166361A1 (en) * | 2004-12-21 | 2006-07-27 | Agnieszka Seyda | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
EP1838842A2 (en) * | 2004-12-23 | 2007-10-03 | Ethicon, Incorporated | Treatment of osteochondral diseases using postpartum-derived cells and products thereof |
EP1831355A2 (en) * | 2004-12-23 | 2007-09-12 | Ethicon, Inc. | Soft tissue repair and regeneration using postpartum-derived cells and cell products |
PL1831356T3 (en) * | 2004-12-23 | 2017-07-31 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US20060147429A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Facilitated cellular reconstitution of organs and tissues |
US20060148080A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Methods for supporting and producing human cells and tissues in non-human mammal hosts |
WO2006088867A2 (en) * | 2005-02-15 | 2006-08-24 | Medistem Laboratories, Incorporated | Method for expansion of stem cells |
US20060222634A1 (en) * | 2005-03-31 | 2006-10-05 | Clarke Diana L | Amnion-derived cell compositions, methods of making and uses thereof |
US8153430B2 (en) * | 2005-03-31 | 2012-04-10 | Stemnion, Inc. | Methods related to surgery |
US20090202431A1 (en) * | 2005-04-08 | 2009-08-13 | University Of Florida Research Foundation, Inc. | Stem-like cells in bone sarcomas |
CN101252957A (en) * | 2005-06-30 | 2008-08-27 | 人类起源公司 | Repair of tympanic membrane using placenta derived collagen biofabric |
WO2007009062A2 (en) * | 2005-07-13 | 2007-01-18 | Anthrogenesis Corporation | Treatment of leg ulcers using placenta derived collagen biofabric |
WO2007009061A2 (en) * | 2005-07-13 | 2007-01-18 | Anthrogenesis Corporation | Ocular plug formed from placenta derived collagen biofabric |
EP1941032A2 (en) | 2005-10-14 | 2008-07-09 | Regents Of The University Of Minnesota | Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype |
WO2007073552A1 (en) * | 2005-12-19 | 2007-06-28 | Ethicon, Inc. | In vitro expansion of postpartum derived cells in roller bottles |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
WO2007076522A2 (en) * | 2005-12-28 | 2007-07-05 | Ethicon, Incorporated | Treatment of peripheral vascular disease using postpartum-derived cells |
EP1976978A2 (en) * | 2005-12-29 | 2008-10-08 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
US8871198B2 (en) * | 2006-03-29 | 2014-10-28 | Stemnion, Inc. | Methods related to wound healing |
US20070178073A1 (en) * | 2006-02-01 | 2007-08-02 | Samsung Life Public Welfare Foundation | Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease |
WO2007106063A2 (en) * | 2006-02-24 | 2007-09-20 | Genzyme Corporation | Methods for increasing blood flow and/or promoting tissue regeneration |
PT2366775E (en) * | 2006-03-23 | 2015-07-20 | Pluristem Ltd | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
US20110171182A1 (en) * | 2006-03-23 | 2011-07-14 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
CN101558151B (en) * | 2006-03-23 | 2015-10-21 | 普拉里斯坦有限公司 | The purposes that methods for cell expansion and the cell produced by this and conditioned medium are used for the treatment of |
EP1999255A2 (en) | 2006-03-24 | 2008-12-10 | The Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
US7727763B2 (en) * | 2006-04-17 | 2010-06-01 | Bioe, Llc | Differentiation of multi-lineage progenitor cells to respiratory epithelial cells |
US20080050814A1 (en) * | 2006-06-05 | 2008-02-28 | Cryo-Cell International, Inc. | Procurement, isolation and cryopreservation of fetal placental cells |
WO2007146106A2 (en) * | 2006-06-05 | 2007-12-21 | Cryo- Cell International, Inc. | Procurement, isolation and cryopreservation of maternal placental cells |
US20080044848A1 (en) * | 2006-06-09 | 2008-02-21 | Heidaran Mohammad A | Placental niche and use thereof to culture stem cells |
WO2007145889A1 (en) | 2006-06-14 | 2007-12-21 | Stemnion, Inc. | Methods of treating spinal cord injury and minimizing scarring |
US7993918B2 (en) * | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
WO2008021391A1 (en) * | 2006-08-15 | 2008-02-21 | Anthrogenesis Corporation | Umbilical cord biomaterial for medical use |
US8372437B2 (en) | 2006-08-17 | 2013-02-12 | Mimedx Group, Inc. | Placental tissue grafts |
US20080131522A1 (en) * | 2006-10-03 | 2008-06-05 | Qing Liu | Use of placental biomaterial for ocular surgery |
US8071135B2 (en) | 2006-10-04 | 2011-12-06 | Anthrogenesis Corporation | Placental tissue compositions |
CA2665369C (en) | 2006-10-06 | 2023-01-10 | Anthrogenesis Corporation | Human placental collagen compositions, and methods of making and using the same |
US8506949B2 (en) | 2007-01-17 | 2013-08-13 | Stemnion, Inc. | Methods for modulating inflammatory and/or immune responses |
ES2623141T3 (en) | 2007-01-17 | 2017-07-10 | Noveome Biotherapeutics, Inc. | New methods to modulate inflammatory and / or immune responses |
NZ597779A (en) * | 2007-02-12 | 2013-07-26 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
US20100172830A1 (en) * | 2007-03-29 | 2010-07-08 | Cellx Inc. | Extraembryonic Tissue cells and method of use thereof |
TWM322542U (en) * | 2007-05-23 | 2007-11-21 | Universal Scient Ind Co Ltd | Testing machine |
AU2008255634B2 (en) * | 2007-05-28 | 2014-06-05 | Monash University | Treatment of chronic lung disease |
KR100900309B1 (en) * | 2007-05-29 | 2009-06-02 | 차의과학대학교 산학협력단 | Process for the high-purity isolation of mesenchymal stem cells derived from placental chorionic plate membrane |
KR20080104844A (en) * | 2007-05-29 | 2008-12-03 | 포천중문의과대학교 산학협력단 | Process for the isolation of placenta-derived trophoblast stem cells |
WO2008156659A1 (en) | 2007-06-18 | 2008-12-24 | Children's Hospital & Research Center At Oakland | Method of isolating stem and progenitor cells from placenta |
JP5196890B2 (en) * | 2007-06-29 | 2013-05-15 | オリンパス株式会社 | Nucleated cell recovery apparatus and nucleated cell recovery method |
WO2009014668A2 (en) * | 2007-07-24 | 2009-01-29 | Stemnion, Inc. | Methods for promoting hair growth |
US20090029463A1 (en) * | 2007-07-25 | 2009-01-29 | Bioe, Inc. | Differentiation of Multi-Lineage Progenitor Cells to Chondrocytes |
JP2010534653A (en) * | 2007-07-27 | 2010-11-11 | イミューンリジェン バイオサイエンシズ,インク. | Method and composition for stimulating stem cell proliferation or differentiation using substance P or analogs thereof |
US9200253B1 (en) | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
CA2736663C (en) | 2007-09-07 | 2018-01-02 | Surgical Biologics, Llc. | Placental tissue grafts and improved methods of preparing and using the same |
CN101978045A (en) * | 2007-09-26 | 2011-02-16 | 细胞基因细胞疗法公司 | Angiogenic cells from human placental perfusate |
EP3524253A1 (en) * | 2007-09-28 | 2019-08-14 | Celularity, Inc. | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
UA99152C2 (en) * | 2007-10-05 | 2012-07-25 | Этикон, Инкорпорейтед | Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells |
US20090239217A1 (en) * | 2007-10-08 | 2009-09-24 | University Of Florida Research Foundation, Inc. | Stem-like cells in bone sarcomas |
KR101046188B1 (en) | 2007-11-30 | 2011-07-04 | 주식회사 알앤엘바이오 | Cell therapy of urinary incontinence containing decidual or adipose derived stem cells |
US8236538B2 (en) | 2007-12-20 | 2012-08-07 | Advanced Technologies And Regenerative Medicine, Llc | Methods for sterilizing materials containing biologically active agents |
EP2245141B1 (en) * | 2008-01-18 | 2018-03-14 | Regents of the University of Minnesota | Stem cell aggregates and methods for making and using |
CA2719825C (en) * | 2008-03-27 | 2018-11-06 | Biolife Solutions, Inc. | Materials and methods for hypothermic collection of whole blood |
CA2724839A1 (en) * | 2008-05-21 | 2009-11-26 | Bioe Llc | Differentiation of multi-lineage progenitor cells to pancreatic cells |
KR20180108887A (en) * | 2008-08-20 | 2018-10-04 | 안트로제네시스 코포레이션 | Treatment of stroke using isolated placental cells |
CA2734446C (en) | 2008-08-22 | 2017-06-20 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
CN101889079B (en) * | 2008-10-17 | 2012-08-08 | 宁夏医科大学附属医院 | A method for constructing human placental mesenchymal cells library which is suitable for clinical applicationc |
EP2362899A1 (en) | 2008-10-31 | 2011-09-07 | Katholieke Universiteit Leuven | Optimized methods for differentiation of cells into cells with hepatocyte and hepatocyte progenitor phenotypes, cells produced by the methods, and methods for using the cells |
US8343480B2 (en) * | 2008-11-14 | 2013-01-01 | Howmedica Osteonics Corp. | Administration of stem or progenitor cells to a joint to enhance recovery from joint surgery |
RU2562154C2 (en) * | 2008-11-19 | 2015-09-10 | Антродженезис Корпорейшн | Amniotic adhesive cells |
WO2010060031A1 (en) * | 2008-11-21 | 2010-05-27 | Anthrogenesis Corporation | Treatment of diseases, disorders or conditions of the lung using placental cells |
ES2520393T3 (en) * | 2008-12-19 | 2014-11-11 | DePuy Synthes Products, LLC | Cells derived from umbilical cord tissue to treat neuropathic pain and spasticity |
JP6095893B2 (en) * | 2008-12-19 | 2017-03-15 | デピュイ・シンセス・プロダクツ・インコーポレイテッド | Regeneration and repair of nerve tissue after injury |
US8771677B2 (en) * | 2008-12-29 | 2014-07-08 | Vladimir B Serikov | Colony-forming unit cell of human chorion and method to obtain and use thereof |
US9205177B2 (en) * | 2009-03-04 | 2015-12-08 | Peytant Solutions, Inc. | Stents modified with material comprising amnion tissue and corresponding processes |
ES2713524T3 (en) | 2009-03-25 | 2019-05-22 | Celularity Inc | Tumor suppression using intermediate natural cytolytic lymphocytes obtained from human placenta and immunomodulatory compounds |
US20100323446A1 (en) | 2009-06-05 | 2010-12-23 | Jill Renee Barnett | Method of collecting placental cells |
US8796315B2 (en) | 2009-06-25 | 2014-08-05 | Darlene E. McCord | Methods for improved wound closure employing olivamine and human umbilical vein endothelial cells |
CA2767014C (en) | 2009-07-02 | 2022-01-25 | Anthrogenesis Corporation | Method of producing erythrocytes without feeder cells |
SG10201913618WA (en) * | 2009-07-21 | 2020-03-30 | Abt Holding Co | Use of stem cells to reduce leukocyte extravasation |
DK2456853T3 (en) * | 2009-07-21 | 2021-02-01 | Abt Holding Co | USE OF STEM CELLS TO REDUCE LEUCOCYT EXTRAVASATION |
EP2493547A4 (en) * | 2009-10-27 | 2013-06-19 | Cedars Sinai Medical Center | External magnetic force for targeted cell delivery with enhanced cell retention |
ES2646750T3 (en) | 2010-01-26 | 2017-12-15 | Anthrogenesis Corporation | Treatment of bone-related cancers using placental stem cells |
US20110212065A1 (en) | 2010-02-18 | 2011-09-01 | Timothy Jansen | Methods of manufacture of therapeutic products comprising vitalized placental dispersions |
WO2011106476A1 (en) * | 2010-02-25 | 2011-09-01 | Abt Holding Company | Modulation of microglia activation |
US20110206647A1 (en) * | 2010-02-25 | 2011-08-25 | Abt Holding Company | Modulation of Angiogenesis |
WO2011109717A1 (en) * | 2010-03-04 | 2011-09-09 | Cryo-Cell International, Inc. | Methods and processes for collecting, preserving, and culturing adult stem cells obtained from lochia and related compositions of matter |
TWI578993B (en) | 2010-04-07 | 2017-04-21 | 安瑟吉納西斯公司 | Angiogenesis using placental stem cells |
TW201138792A (en) | 2010-04-08 | 2011-11-16 | Anthrogenesis Corp | Treatment of sarcoidosis using placental stem cells |
US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
CA3128483A1 (en) | 2010-05-12 | 2011-11-17 | Abt Holding Company | Modulation of splenocytes in cell therapy |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US8840665B2 (en) | 2010-06-11 | 2014-09-23 | Liventa Bioscience, Inc. | Method of tendon repair with amnion and chorion constructs |
WO2011158125A2 (en) | 2010-06-17 | 2011-12-22 | Katholieke Universiteit Leuven | Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells |
KR20130093091A (en) | 2010-07-13 | 2013-08-21 | 안트로제네시스 코포레이션 | Methods of generating natural killer cells |
EP2609191B1 (en) | 2010-08-24 | 2017-11-22 | Regents Of The University Of Minnesota | Non-static suspension culture of cell aggregates |
US8895291B2 (en) | 2010-10-08 | 2014-11-25 | Terumo Bct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
CN104204190B (en) | 2010-10-18 | 2017-02-01 | 尚翔股份有限公司 | Human multipotent embryonic stem cell-like progenitor cells |
US8574899B2 (en) | 2010-12-22 | 2013-11-05 | Vladimir B Serikov | Methods for augmentation collection of placental hematopoietic stem cells and uses thereof |
US20120171161A1 (en) | 2010-12-30 | 2012-07-05 | Sascha Abramson | Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof |
AR084753A1 (en) | 2010-12-30 | 2013-06-05 | Anthrogenesis Corp | COMPOSITIONS THAT INCLUDE ADHERENT CELLS DERIVED FROM AMNIOTIC SACO (AMDAC) AND PLASMA RICH IN PLATES (PRP) |
EP2658557A1 (en) | 2010-12-31 | 2013-11-06 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory rna molecules |
CA2823689C (en) * | 2011-01-10 | 2019-10-08 | Stemnion, Inc. | Methods for accelerating the healing of connective tissue injuries and disorders |
KR102331661B1 (en) | 2011-02-14 | 2021-11-25 | 미메딕스 그룹 인크. | Micronized placental tissue compositions and methods for making and using the same |
EP2675465B1 (en) | 2011-02-14 | 2020-07-01 | MIMEDX Group Inc. | Tissue grafts modified with a cross-linking agent and method of making and using the same |
US8709401B2 (en) | 2011-02-25 | 2014-04-29 | Howmedica Osteonics Corp. | Primed stem cells and uses thereof to treat inflammatory conditions in joints |
WO2013019857A2 (en) | 2011-08-01 | 2013-02-07 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
US9168030B2 (en) | 2011-08-11 | 2015-10-27 | Robert A. Dracker | Envelope and procurement stand for placental transport and stem cell collection |
WO2013055476A1 (en) | 2011-09-09 | 2013-04-18 | Anthrogenesis Corporation | Treatment of amyotrophic lateral sclerosis using placental stem cells |
EP2793745B1 (en) | 2011-12-22 | 2019-07-31 | MIMEDX Group Inc. | Cross-linked dehydrated placental tissue grafts and methods for making and using the same |
EP3338548B1 (en) | 2012-02-23 | 2020-04-08 | Celularity, Inc. | Identification of antitumor compounds using placenta |
US8961617B2 (en) | 2012-03-08 | 2015-02-24 | Liventa Bioscience, Inc. | Amnion and chorion constructs and uses thereof in abdominal surgery |
US20130309210A1 (en) * | 2012-05-18 | 2013-11-21 | Regen Biopharma, Inc | Acceleration of hematopoietic reconstitution by placental endothelial and endothelial progenitor cells |
JP2015521054A (en) | 2012-06-05 | 2015-07-27 | カプリコール,インコーポレイテッド | Optimized methods for generating cardiac stem cells from heart tissue and their use in cardiac therapy |
KR20150063374A (en) | 2012-08-13 | 2015-06-09 | 안트로제네시스 코포레이션 | Natural killer cells and uses therof |
CA2881394A1 (en) | 2012-08-13 | 2014-02-20 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
US9943551B2 (en) | 2012-08-15 | 2018-04-17 | Mimedx Group, Inc. | Tissue grafts composed of micronized placental tissue and methods of making and using the same |
EP2884944B1 (en) | 2012-08-15 | 2020-10-07 | MiMedx Group, Inc. | Reinforced placental tissue grafts and methods of making and using the same |
US11338063B2 (en) | 2012-08-15 | 2022-05-24 | Mimedx Group, Inc. | Placental tissue grafts modified with a cross-linking agent and methods of making and using the same |
US8904664B2 (en) | 2012-08-15 | 2014-12-09 | Mimedx Group, Inc. | Dehydration device and methods for drying biological materials |
CN104769101A (en) | 2012-09-04 | 2015-07-08 | 人类起源公司 | Methods of tissue generation |
US9180145B2 (en) | 2012-10-12 | 2015-11-10 | Mimedx Group, Inc. | Compositions and methods for recruiting and localizing stem cells |
CA2888772A1 (en) | 2012-10-19 | 2015-04-24 | Anthrogenesis Corporation | Treatment of pain using amnion derived adherent cells |
US9155799B2 (en) | 2012-11-19 | 2015-10-13 | Mimedx Group, Inc. | Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent |
US8946163B2 (en) | 2012-11-19 | 2015-02-03 | Mimedx Group, Inc. | Cross-linked collagen comprising metallic anticancer agents |
SG11201504116SA (en) * | 2012-11-30 | 2015-06-29 | Pharmacosmos As | Cryoprotecting agent, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation |
WO2014085613A1 (en) | 2012-11-30 | 2014-06-05 | Mccord Darlene E | Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition |
EP2928481A4 (en) | 2012-12-07 | 2016-09-14 | Anthrogenesis Corp | Treating oral lesions using placental extracellular matrix |
JP2016502844A (en) | 2012-12-14 | 2016-02-01 | アントフロゲネシス コーポレーション | Anoikis-resistant placental stem cells and uses thereof |
AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
US9827293B2 (en) | 2013-01-17 | 2017-11-28 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
US10517931B2 (en) | 2013-01-17 | 2019-12-31 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
US9655948B1 (en) | 2013-01-17 | 2017-05-23 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
EP2945639B1 (en) | 2013-01-18 | 2020-09-30 | MIMEDX Group Inc. | Methods for treating cardiac conditions |
US10206977B1 (en) | 2013-01-18 | 2019-02-19 | Mimedx Group, Inc. | Isolated placental stem cell recruiting factors |
WO2014164669A1 (en) | 2013-03-13 | 2014-10-09 | Stemnion, Inc. | Improved medical device |
JP2013164854A (en) * | 2013-03-13 | 2013-08-22 | Action Research:Kk | Automatic control device and method for self-decomposition mechanism |
US10329529B2 (en) | 2013-03-14 | 2019-06-25 | Celularity, Inc. | Enhanced placental stem cells and uses thereof |
US10029030B2 (en) | 2013-03-15 | 2018-07-24 | Mimedx Group, Inc. | Molded placental tissue compositions and methods of making and using the same |
ES2837628T3 (en) | 2013-03-15 | 2021-07-01 | Celgene Corp | Modified T lymphocytes |
NO2975611T3 (en) | 2013-03-15 | 2018-06-09 | ||
EP2970913B1 (en) | 2013-03-15 | 2018-08-22 | LongBoat Explorers AB | Cells, methods and apparatuses for umbilical cord blood collection and isolation of cells |
BR112015025252A2 (en) | 2013-04-02 | 2017-07-18 | Celgene Corp | methods and compositions using 4-amino-2- (2,6-dioxo-piperidin-3-yl) -isoindoline-1,3-dione for treatment and management of central nervous system cancers |
SG10201914136UA (en) | 2013-04-12 | 2020-03-30 | Saverio Lafrancesca | Improving organs for transplantation |
US9446142B2 (en) | 2013-05-28 | 2016-09-20 | Mimedx Group, Inc. | Polymer chelator conjugates |
EP3862422A1 (en) | 2013-06-24 | 2021-08-11 | Celularity Inc. | Extracellular matrix composition beads for cell culture |
KR20160075676A (en) | 2013-10-24 | 2016-06-29 | 오스페달레 산 라파엘 에스.알.엘. | Method |
CN105992816B (en) | 2013-11-16 | 2018-04-17 | 泰尔茂比司特公司 | Cell amplification in bioreactor |
CN103756957B (en) * | 2014-01-27 | 2015-11-18 | 山东省齐鲁干细胞工程有限公司 | A kind of method of wash-out endothelial progenitor cells from placenta |
JP6783143B2 (en) | 2014-03-25 | 2020-11-11 | テルモ ビーシーティー、インコーポレーテッド | Passive replenishment of medium |
WO2016007827A1 (en) | 2014-07-11 | 2016-01-14 | Anthrogenesis Corporation | Methods of improving vector transduction efficiency into t lymphocytes |
EP3828267A3 (en) | 2014-08-12 | 2021-08-11 | Celgene Corporation | Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract |
JP7099822B2 (en) | 2014-08-28 | 2022-07-12 | ミメディクス グループ インコーポレイテッド | Collagen-enhanced tissue graft |
WO2016049421A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled feed |
CA2962444C (en) | 2014-10-03 | 2023-09-05 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
US20160095307A1 (en) * | 2014-10-07 | 2016-04-07 | NuTech Medical, Inc. | Method and composition for hypothermic storage of placental tissue |
CN107106615A (en) | 2014-10-09 | 2017-08-29 | 人类起源公司 | The attached cell excretion body in placenta source and application thereof |
US10765705B2 (en) | 2014-11-24 | 2020-09-08 | Prime Merger Sub, Llc | Visco-supplement compositions, and methods of use thereof |
EP3297694A1 (en) | 2015-05-21 | 2018-03-28 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
CN108367028A (en) | 2015-09-15 | 2018-08-03 | 细胞结构公司 | Diabetic peripheral neuropathy is treated using placenta cells |
EP3402543B1 (en) | 2016-01-11 | 2021-09-08 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
SG10201914102UA (en) | 2016-01-21 | 2020-03-30 | Abt Holding Co | Stem cells for wound healing |
WO2017210652A1 (en) | 2016-06-03 | 2017-12-07 | Cedars-Sinai Medical Center | Cdc-derived exosomes for treatment of ventricular tachyarrythmias |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
WO2018013693A1 (en) | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof |
EP3515459A4 (en) | 2016-09-20 | 2020-08-05 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
WO2018073615A1 (en) | 2016-10-21 | 2018-04-26 | Longboat Explorers Ab | Methods and compositions for generating hematopoietic cells |
WO2018106742A1 (en) | 2016-12-05 | 2018-06-14 | Celularity, Inc. | Treatment of lymphedema and related conditions using placental adherent cells |
EP3656842A1 (en) | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Cell expansion |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
EP3612191A4 (en) | 2017-04-19 | 2020-12-30 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
CA3077325A1 (en) | 2017-09-28 | 2019-04-04 | Celularity Inc. | Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody |
US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
EA202191508A1 (en) | 2018-11-30 | 2021-09-21 | Селулэрити Инк. | REPRODUCTION OF NATURAL KILLER CELLS AND ILC3 CELLS USING NEW AROMATIC COMPOUNDS |
WO2020252464A1 (en) | 2019-06-14 | 2020-12-17 | Celularity Inc. | Populations of natural killer cells for treating cancers |
US20220273716A1 (en) | 2019-07-25 | 2022-09-01 | Celularity Inc. | Populations of natural killer cells comprising a cd38 chimeric antigen receptor |
US20230355759A1 (en) | 2019-07-31 | 2023-11-09 | Celularity Inc. | Populations of natural killer cells comprising a cleavage resistant cd16 |
US20220372444A1 (en) | 2019-10-18 | 2022-11-24 | Amniotics Ab | Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof |
WO2021113849A1 (en) | 2019-12-05 | 2021-06-10 | Celularity Inc. | Her2+ cancer treatment with populations of natural killer cells comprising a cleavage resistant cd16 |
CN111172109A (en) * | 2019-12-20 | 2020-05-19 | 广州海润康华生物科技有限公司 | Immune cell culture method and application thereof |
US20220000919A1 (en) | 2020-01-29 | 2022-01-06 | Celularity Inc. | Placental derived natural killer cells for treatment of coronavirus infections |
US20230210909A1 (en) | 2020-05-08 | 2023-07-06 | Celularity Inc. | Placenta-derived adherent (pda) stem cell for the treatment of adults with sars-cov-2 related acute respiratory failure and ards (covid-19) |
CN111979178B (en) * | 2020-08-20 | 2021-04-02 | 创芯国际生物科技(广州)有限公司 | Culture medium and culture method for animal lung bud organoid |
WO2023278628A1 (en) | 2021-06-29 | 2023-01-05 | Celularity Inc. | Human placental hematopoietic stem cell derived natural killer cells in acute myeloid leukemia (aml) remission with minimal residual disease (mrd) or relapsed/refractory aml |
WO2023010123A1 (en) | 2021-07-29 | 2023-02-02 | Celularity Inc. | Placenta-dervied nk cells as a senolytic for therapeutic and other uses |
WO2023137344A1 (en) | 2022-01-11 | 2023-07-20 | Celularity Inc. | Cleavage resistant cd16 constructs and uses thereof |
CN116144583B (en) * | 2023-04-19 | 2023-08-25 | 北京雪颜博润生物科技有限公司 | Method for obtaining human placenta embryo-derived stem cells and application |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998037903A1 (en) * | 1997-02-28 | 1998-09-03 | Tseng Scheffer C G | Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries |
Family Cites Families (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2877299A (en) * | 1956-01-25 | 1959-03-10 | Philco Corp | Multi-function apparatus for television receivers |
US3862002A (en) * | 1962-05-08 | 1975-01-21 | Sanfar Lab Inc | Production of physiologically active placental substances |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4829000A (en) * | 1985-08-30 | 1989-05-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Reconstituted basement membrane complex with biological activity |
US5902741A (en) | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
US5863531A (en) | 1986-04-18 | 1999-01-26 | Advanced Tissue Sciences, Inc. | In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework |
US5192553A (en) * | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
US5004681B1 (en) * | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
FR2646438B1 (en) | 1989-03-20 | 2007-11-02 | Pasteur Institut | A METHOD FOR SPECIFIC REPLACEMENT OF A COPY OF A GENE PRESENT IN THE RECEIVER GENOME BY INTEGRATION OF A GENE DIFFERENT FROM THAT OR INTEGRATION |
US5605822A (en) * | 1989-06-15 | 1997-02-25 | The Regents Of The University Of Michigan | Methods, compositions and devices for growing human hematopoietic cells |
US5763266A (en) * | 1989-06-15 | 1998-06-09 | The Regents Of The University Of Michigan | Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells |
US5399493A (en) * | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
US5437994A (en) * | 1989-06-15 | 1995-08-01 | Regents Of The University Of Michigan | Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
US5635386A (en) * | 1989-06-15 | 1997-06-03 | The Regents Of The University Of Michigan | Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture |
EP0437576B1 (en) | 1989-07-25 | 2002-07-03 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
AU635844B2 (en) | 1989-11-06 | 1993-04-01 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
US5061620A (en) * | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5635387A (en) * | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
US6326198B1 (en) | 1990-06-14 | 2001-12-04 | Regents Of The University Of Michigan | Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US5226914A (en) * | 1990-11-16 | 1993-07-13 | Caplan Arnold I | Method for treating connective tissue disorders |
US5197985A (en) * | 1990-11-16 | 1993-03-30 | Caplan Arnold I | Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells |
US5733542A (en) * | 1990-11-16 | 1998-03-31 | Haynesworth; Stephen E. | Enhancing bone marrow engraftment using MSCS |
US6010696A (en) * | 1990-11-16 | 2000-01-04 | Osiris Therapeutics, Inc. | Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells |
US5811094A (en) * | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
US5837539A (en) * | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
US5190556A (en) | 1991-03-19 | 1993-03-02 | O.B. Tech, Inc. | Cord cutter sampler |
US5744361A (en) * | 1991-04-09 | 1998-04-28 | Indiana University | Expansion of human hematopoietic progenitor cells in a liquid medium |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US6057123A (en) * | 1991-12-23 | 2000-05-02 | British Biotech Pharmaceuticals Limited | Stem cell inhibiting proteins |
WO1993020228A1 (en) * | 1992-03-31 | 1993-10-14 | Toray Industries, Inc. | Novel, physiologically active protein and hemopoietic stem cell growth promoter |
US5460964A (en) * | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
AU4543193A (en) * | 1992-06-22 | 1994-01-24 | Henry E. Young | Scar inhibitory factor and use thereof |
US5672346A (en) * | 1992-07-27 | 1997-09-30 | Indiana University Foundation | Human stem cell compositions and methods |
US5672499A (en) * | 1992-07-27 | 1997-09-30 | California Institute Of Technology | Immoralized neural crest stem cells and methods of making |
US5849553A (en) | 1992-07-27 | 1998-12-15 | California Institute Of Technology | Mammalian multipotent neural stem cells |
WO1994011493A1 (en) * | 1992-11-16 | 1994-05-26 | Applied Immune Sciences, Inc. | Pluripotential quiescent stem cell population |
US5772992A (en) | 1992-11-24 | 1998-06-30 | G.D. Searle & Co. | Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors |
US5654186A (en) * | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
DK0691988T3 (en) * | 1993-03-31 | 2003-04-14 | Wellstat Therapeutics Corp | Inhibitor of stem cell proliferation and applications thereof |
GB9308271D0 (en) * | 1993-04-21 | 1993-06-02 | Univ Edinburgh | Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method |
US5709854A (en) | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
US5372581A (en) | 1993-07-21 | 1994-12-13 | Minneapolis Children's Services Corporation | Method and apparatus for placental blood collection |
IL107483A0 (en) | 1993-11-03 | 1994-02-27 | Yeda Res & Dev | Bone marrow transplantation |
US5591625A (en) * | 1993-11-24 | 1997-01-07 | Case Western Reserve University | Transduced mesenchymal stem cells |
US6288030B1 (en) * | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
US6001654A (en) | 1994-01-28 | 1999-12-14 | California Institute Of Technology | Methods for differentiating neural stem cells to neurons or smooth muscle cells using TGT-β super family growth factors |
US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
DE69531638T2 (en) * | 1994-06-06 | 2004-06-17 | Osiris Therapeutics, Inc. | BIOMATRIX FOR TISSUE REGENATION |
US6174333B1 (en) * | 1994-06-06 | 2001-01-16 | Osiris Therapeutics, Inc. | Biomatrix for soft tissue regeneration using mesenchymal stem cells |
DE4422667A1 (en) * | 1994-06-30 | 1996-01-04 | Boehringer Ingelheim Int | Process for the production and cultivation of hematopoietic progenitor cells |
US6103522A (en) * | 1994-07-20 | 2000-08-15 | Fred Hutchinson Cancer Research Center | Human marrow stromal cell lines which sustain hematopoiesis |
US5516532A (en) | 1994-08-05 | 1996-05-14 | Children's Medical Center Corporation | Injectable non-immunogenic cartilage and bone preparation |
US5827742A (en) * | 1994-09-01 | 1998-10-27 | Beth Israel Deaconess Medical Center, Inc. | Method of selecting pluripotent hematopioetic progenitor cells |
US5665557A (en) * | 1994-11-14 | 1997-09-09 | Systemix, Inc. | Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof |
DE69527540T2 (en) | 1994-11-16 | 2003-01-30 | Amgen Inc | USE OF STEM CELL FACTOR AND SOLUBLE INTERLEUKIN-6 RECEPTOR FOR THE PROPAGATION OF HEMATOPOIETIC PRECELLER CELLS |
US5914268A (en) * | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
US5874301A (en) * | 1994-11-21 | 1999-02-23 | National Jewish Center For Immunology And Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
US5789147A (en) | 1994-12-05 | 1998-08-04 | New York Blood Center, Inc. | Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood |
US5736396A (en) * | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
US5695998A (en) * | 1995-02-10 | 1997-12-09 | Purdue Research Foundation | Submucosa as a growth substrate for islet cells |
US6011000A (en) * | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
US5906934A (en) * | 1995-03-14 | 1999-05-25 | Morphogen Pharmaceuticals, Inc. | Mesenchymal stem cells for cartilage repair |
US5716616A (en) * | 1995-03-28 | 1998-02-10 | Thomas Jefferson University | Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects |
US5733541A (en) * | 1995-04-21 | 1998-03-31 | The Regent Of The University Of Michigan | Hematopoietic cells: compositions and methods |
US5925567A (en) * | 1995-05-19 | 1999-07-20 | T. Breeders, Inc. | Selective expansion of target cell populations |
US5908782A (en) * | 1995-06-05 | 1999-06-01 | Osiris Therapeutics, Inc. | Chemically defined medium for human mesenchymal stem cells |
US5830708A (en) | 1995-06-06 | 1998-11-03 | Advanced Tissue Sciences, Inc. | Methods for production of a naturally secreted extracellular matrix |
WO1996040875A1 (en) * | 1995-06-07 | 1996-12-19 | Novartis Ag | Methods for obtaining compositions enriched for hematopoietic stem cells and antibodies for use therein |
US5654381A (en) | 1995-06-16 | 1997-08-05 | Massachusetts Institute Of Technology | Functionalized polyester graft copolymers |
US5877299A (en) | 1995-06-16 | 1999-03-02 | Stemcell Technologies Inc. | Methods for preparing enriched human hematopoietic cell preparations |
US6306575B1 (en) * | 1995-06-16 | 2001-10-23 | Stemcell Technologies, Inc. | Methods for preparing enriched human hematopoietic cell preparations |
US5800539A (en) | 1995-11-08 | 1998-09-01 | Emory University | Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease |
US5858782A (en) * | 1995-11-13 | 1999-01-12 | Regents Of The University Of Michigan | Functional human hematopoietic cells |
US5922597A (en) * | 1995-11-14 | 1999-07-13 | Regents Of The University Of Minnesota | Ex vivo culture of stem cells |
JP3781433B2 (en) * | 1995-11-16 | 2006-05-31 | ケース ウエスターン リザーブ ユニバーシティ | In vitro chondrogenesis induction of human mesenchymal stem cells |
WO1997019172A1 (en) * | 1995-11-17 | 1997-05-29 | Asahi Kasei Kogyo Kabushiki Kaisha | Differentiation-suppressive polypeptide |
US5716794A (en) * | 1996-03-29 | 1998-02-10 | Xybernaut Corporation | Celiac antigen |
EP2105138A3 (en) * | 1996-04-19 | 2013-06-05 | Osiris Therapeutics, Inc. | Regeneration and augmentation of bone using mesenchymal stem cells |
WO1997041208A1 (en) * | 1996-04-26 | 1997-11-06 | Case Western Reserve University | Skin regeneration using mesenchymal stem cells |
US5919176A (en) * | 1996-05-14 | 1999-07-06 | Children's Hospital Medical Center Of Northern California | Apparatus and method for collecting blood from an umbilical cord |
US5827740A (en) * | 1996-07-30 | 1998-10-27 | Osiris Therapeutics, Inc. | Adipogenic differentiation of human mesenchymal stem cells |
US5851984A (en) | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
US5916202A (en) * | 1996-08-30 | 1999-06-29 | Haswell; John N. | Umbilical cord blood collection |
US6227202B1 (en) * | 1996-09-03 | 2001-05-08 | Maulana Azad Medical College | Method of organogenesis and tissue regeneration/repair using surgical techniques |
US5945337A (en) * | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
US5919702A (en) * | 1996-10-23 | 1999-07-06 | Advanced Tissue Science, Inc. | Production of cartilage tissue using cells isolated from Wharton's jelly |
US5969105A (en) * | 1996-10-25 | 1999-10-19 | Feng; Yiqing | Stem cell factor receptor agonists |
US6335195B1 (en) | 1997-01-28 | 2002-01-01 | Maret Corporation | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
EP1028737B1 (en) * | 1997-07-03 | 2007-04-04 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells from peripheral blood |
US7514074B2 (en) * | 1997-07-14 | 2009-04-07 | Osiris Therapeutics, Inc. | Cardiac muscle regeneration using mesenchymal stem cells |
ATE307195T1 (en) * | 1997-07-14 | 2005-11-15 | Osiris Therapeutics Inc | CARDIAC MUSCLE REGENERATION USING MESENCHYMAL STEM CELLS |
US6077708A (en) * | 1997-07-18 | 2000-06-20 | Collins; Paul C. | Method of determining progenitor cell content of a hematopoietic cell culture |
US5879318A (en) * | 1997-08-18 | 1999-03-09 | Npbi International B.V. | Method of and closed system for collecting and processing umbilical cord blood |
WO1999011287A1 (en) * | 1997-09-04 | 1999-03-11 | Osiris Therapeutics, Inc. | Ligands that modulate differentiation of mesenchymal stem cells |
US5968829A (en) * | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
US6093531A (en) * | 1997-09-29 | 2000-07-25 | Neurospheres Holdings Ltd. | Generation of hematopoietic cells from multipotent neural stem cells |
JPH11137251A (en) * | 1997-11-07 | 1999-05-25 | Chugai Bunshi Igaku Kenkyusho:Kk | Promoter of human p27kip1 gene |
US6248587B1 (en) * | 1997-11-26 | 2001-06-19 | University Of Southern Cailfornia | Method for promoting mesenchymal stem and lineage-specific cell proliferation |
US6059968A (en) | 1998-01-20 | 2000-05-09 | Baxter International Inc. | Systems for processing and storing placenta/umbilical cord blood |
EP1062321B1 (en) * | 1998-03-13 | 2004-12-29 | Osiris Therapeutics, Inc. | Uses for humane non-autologous mesenchymal stem cells |
US6368636B1 (en) * | 1998-03-18 | 2002-04-09 | Osiris Therapeutics, Inc. | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
DK1066052T3 (en) * | 1998-03-18 | 2006-06-12 | Osiris Therapeutics Inc | Mesenchymal stem cells for the prevention and treatment of immune responses in transplants |
DE69910362T2 (en) * | 1998-04-03 | 2004-06-24 | Osiris Therapeutics, Inc. | APPLICATION OF THE MESENCHYMAL STEM CELLS AS IMMUNE SUPPRESSIVA |
WO1999056753A1 (en) * | 1998-05-04 | 1999-11-11 | Point Therapeutics, Inc. | Hematopoietic stimulation |
US6835377B2 (en) * | 1998-05-13 | 2004-12-28 | Osiris Therapeutics, Inc. | Osteoarthritis cartilage regeneration |
EP1078042A1 (en) * | 1998-05-22 | 2001-02-28 | Osiris Therapeutics, Inc. | Production of megakaryocytes by co-culturing human mesenchymal stem cells with cd34+ cells |
ES2292245T3 (en) * | 1998-05-29 | 2008-03-01 | Osiris Therapeutics, Inc. | MESENCHIMATIC MOTHER CELLS CD45 + AND / OR FIBROBLASTO + HUMANAS. |
AU4336599A (en) * | 1998-06-08 | 1999-12-30 | Osiris Therapeutics, Inc. | (in vitro) maintenance of hematopoietic stem cells |
DE69937347T2 (en) | 1998-06-08 | 2008-09-04 | Osiris Therapeutics, Inc. | REGULATION OF HEMATOPOIETIC STEM CELL DIFFERENTIATION THROUGH THE USE OF HUMAN MESENCHYMAL STEM CELLS |
ATE238049T1 (en) * | 1998-07-28 | 2003-05-15 | Synthes Ag | USE OF CREATINE SUBSTANCES TO TREAT BONE AND CARTILAGE CELLS AND TISSUES |
US5958767A (en) * | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
JP3517359B2 (en) * | 1998-09-14 | 2004-04-12 | テルモ株式会社 | Cell separation / collection apparatus and cell separation / collection method |
WO2000027995A1 (en) * | 1998-11-09 | 2000-05-18 | Monash University | Embryonic stem cells |
US6184035B1 (en) * | 1998-11-18 | 2001-02-06 | California Institute Of Technology | Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells |
IN191359B (en) * | 1999-04-20 | 2003-11-29 | Nat Inst Immunology | |
AU4860900A (en) | 1999-06-02 | 2000-12-18 | Lifebank Services, L.L.C. | Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells |
US7015037B1 (en) * | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
US8147824B2 (en) * | 1999-08-05 | 2012-04-03 | Athersys, Inc. | Immunomodulatory properties of multipotent adult progenitor cells and uses thereof |
US8075881B2 (en) * | 1999-08-05 | 2011-12-13 | Regents Of The University Of Minnesota | Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure |
US6239157B1 (en) * | 1999-09-10 | 2001-05-29 | Osiris Therapeutics, Inc. | Inhibition of osteoclastogenesis |
US6685936B2 (en) * | 1999-10-12 | 2004-02-03 | Osiris Therapeutics, Inc. | Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation |
US6280718B1 (en) * | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
IL156303A0 (en) * | 2000-12-06 | 2004-01-04 | Robert J Hariri | Method of collecting placental stem cells |
US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
EP1362095B1 (en) * | 2001-02-14 | 2015-05-27 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
KR101132545B1 (en) * | 2001-02-14 | 2012-04-02 | 안트로제네시스 코포레이션 | Post-partum mammalian placenta, its use and placental stem cells therefrom |
EP1367899A4 (en) * | 2001-02-14 | 2004-07-28 | Leo T Furcht | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
US20020132343A1 (en) * | 2001-03-19 | 2002-09-19 | Clark Lum | System and method for delivering umbilical cord-derived tissue-matched stem cells for transplantation |
CA2396536A1 (en) * | 2001-08-10 | 2003-02-10 | Saiko Uchida | Human stem cells originated from human amniotic mesenchymal cell layer |
US9969980B2 (en) * | 2001-09-21 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
JP4330995B2 (en) * | 2001-11-15 | 2009-09-16 | チルドレンズ メディカル センター コーポレーション | Methods for isolating, proliferating, and differentiating fetal stem cells from chorionic villi, amniotic fluid, and placenta, and methods for their therapeutic use |
US7736892B2 (en) * | 2002-02-25 | 2010-06-15 | Kansas State University Research Foundation | Cultures, products and methods using umbilical cord matrix cells |
WO2003077864A2 (en) * | 2002-03-15 | 2003-09-25 | Department Of Veterans Affairs, Rehabilitation R & D Service | Methods and compositions for directing cells to target organs |
US20030187515A1 (en) * | 2002-03-26 | 2003-10-02 | Hariri Robert J. | Collagen biofabric and methods of preparing and using the collagen biofabric |
EP1538913A2 (en) * | 2002-04-12 | 2005-06-15 | Celgene Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US20050148034A1 (en) * | 2002-04-12 | 2005-07-07 | Hariri Robert J. | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
US20030235563A1 (en) * | 2002-04-19 | 2003-12-25 | Strom Stephen C. | Placental derived stem cells and uses thereof |
CN1668733A (en) * | 2002-05-30 | 2005-09-14 | 细胞基因公司 | Methods of using JNK or MKK inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
US7422736B2 (en) * | 2002-07-26 | 2008-09-09 | Food Industry Research And Development Institute | Somatic pluripotent cells |
ES2560847T3 (en) * | 2002-07-31 | 2016-02-23 | Yves Saint-Laurent Parfums | Stem cells from adipose tissue and differentiated cells from these cells |
WO2004047770A2 (en) * | 2002-11-26 | 2004-06-10 | Anthrogenesis Corporation | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
CA2515469C (en) * | 2003-02-11 | 2013-12-17 | John E. Davies | Progenitor cells from wharton's jelly of human umbilical cord |
KR20050105467A (en) * | 2003-02-13 | 2005-11-04 | 안트로제네시스 코포레이션 | Use of umbilical cord blood to treat individuals having a disease, disorder or condition |
US7875272B2 (en) * | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
US7413734B2 (en) * | 2003-06-27 | 2008-08-19 | Ethicon, Incorporated | Treatment of retinitis pigmentosa with human umbilical cord cells |
WO2005017117A2 (en) * | 2003-08-14 | 2005-02-24 | Martin Haas | Multipotent amniotic fetal stem cells (mafsc) and banking of same |
US20050089513A1 (en) * | 2003-10-28 | 2005-04-28 | Norio Sakuragawa | Side population cells originated from human amnion and their uses |
EP1682654A2 (en) * | 2003-11-10 | 2006-07-26 | Amgen Inc. | Methods of using g-csf mobilized c-kit+cells in the production of embryoid body-like cell clusters for tissue repair and in the treatment of cardiac myopathy |
WO2005055929A2 (en) * | 2003-12-02 | 2005-06-23 | Celgene Corporation | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
US20050176139A1 (en) * | 2004-01-12 | 2005-08-11 | Yao-Chang Chen | Placental stem cell and methods thereof |
EP2824174B1 (en) * | 2004-03-22 | 2018-11-28 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
KR20070002067A (en) * | 2004-03-26 | 2007-01-04 | 셀진 코포레이션 | Systems and methods for providing a stem cell bank |
MX2007001937A (en) * | 2004-08-16 | 2007-08-07 | Cellres Corp Pte Ltd | Isolation of stem/progenitor cells from amniotic membrane of umbilical cord. |
US20060166361A1 (en) * | 2004-12-21 | 2006-07-27 | Agnieszka Seyda | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
WO2006101548A2 (en) * | 2004-12-21 | 2006-09-28 | Ethicon, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same |
AU2005322068B2 (en) * | 2004-12-23 | 2011-09-01 | Ethicon Incorporated | Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells |
US20060222634A1 (en) * | 2005-03-31 | 2006-10-05 | Clarke Diana L | Amnion-derived cell compositions, methods of making and uses thereof |
US7993918B2 (en) * | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
-
2002
- 2002-02-13 EP EP02720974.1A patent/EP1362095B1/en not_active Expired - Lifetime
- 2002-02-13 CA CA3046566A patent/CA3046566A1/en not_active Expired - Lifetime
- 2002-02-13 NZ NZ541541A patent/NZ541541A/en not_active IP Right Cessation
- 2002-02-13 EP EP10182362.3A patent/EP2336301B1/en not_active Expired - Lifetime
- 2002-02-13 EP EP10182195A patent/EP2336299A1/en not_active Withdrawn
- 2002-02-13 US US10/076,180 patent/US20030032179A1/en not_active Abandoned
- 2002-02-13 CA CA2856986A patent/CA2856986C/en not_active Expired - Lifetime
- 2002-02-13 EP EP10182243.5A patent/EP2316919B1/en not_active Expired - Lifetime
- 2002-02-13 EP EP10182433.2A patent/EP2316918B1/en not_active Expired - Lifetime
- 2002-02-13 WO PCT/US2002/004282 patent/WO2002064755A2/en active Application Filing
- 2002-02-13 EP EP10182485.2A patent/EP2314673B1/en not_active Expired - Lifetime
- 2002-02-13 EP EP10182303.7A patent/EP2336300B1/en not_active Expired - Lifetime
- 2002-02-13 IL IL15735002A patent/IL157350A0/en unknown
- 2002-02-13 AU AU2002251935A patent/AU2002251935B2/en not_active Expired
- 2002-02-13 NZ NZ527849A patent/NZ527849A/en not_active IP Right Cessation
- 2002-02-13 MX MXPA03007175A patent/MXPA03007175A/en active IP Right Grant
- 2002-02-13 CA CA2438153A patent/CA2438153C/en not_active Expired - Lifetime
- 2002-02-13 JP JP2002565070A patent/JP2004528021A/en active Pending
-
2003
- 2003-08-12 US US10/640,428 patent/US7255879B2/en not_active Expired - Lifetime
-
2004
- 2004-06-22 US US10/874,828 patent/US7468276B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998037903A1 (en) * | 1997-02-28 | 1998-09-03 | Tseng Scheffer C G | Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries |
Non-Patent Citations (5)
Title |
---|
CONTRACTOR S.F., EATON B.M. ET AL.: "A comparison of the effects of different perfusion regimens on the structure of the isolated human placental lobule" CELL TISSUE RES, vol. 237, 1984, pages 609-617, XP001085129 * |
MOORE J M ET AL: "A simple perfusion technique for isolation of maternal intervillous blood mononuclear cells from human placentae" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 209, no. 1, 10 November 1997 (1997-11-10), pages 93-104, XP004100686 ISSN: 0022-1759 * |
See also references of EP1362095A2 * |
WANG Y., ET AL.: "Enhanced recovery of hematopoietic progenitor and stem cells from cultivated, postpartum human placenta." BLOOD, vol. 98, no. 11/1, 16 November 2001 (2001-11-16), page 183a XP001085063 * |
YE Q., ET AL.: BLOOD, vol. 98, no. 11/1, 16 November 2001 (2001-11-16), page 147B XP001085453 * |
Cited By (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7927587B2 (en) | 1999-08-05 | 2011-04-19 | Regents Of The University Of Minnesota | MAPC administration for the treatment of lysosomal storage disorders |
EP1482787A2 (en) * | 2002-02-13 | 2004-12-08 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
EP2292091A1 (en) | 2002-02-13 | 2011-03-09 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
EP2186407A1 (en) | 2002-02-13 | 2010-05-19 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
EP2301343A1 (en) | 2002-02-13 | 2011-03-30 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
EP1482787A4 (en) * | 2002-02-13 | 2006-02-15 | Anthrogenesis Corp | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
JP2006509770A (en) * | 2002-11-26 | 2006-03-23 | アンソロジェネシス コーポレーション | Cell therapy, cell therapy units, and therapies using them |
WO2004047770A3 (en) * | 2002-11-26 | 2004-08-19 | Anthrogenesis Corp | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
WO2004047770A2 (en) * | 2002-11-26 | 2004-06-10 | Anthrogenesis Corporation | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
EP1601248A4 (en) * | 2003-02-13 | 2010-01-27 | Anthrogenesis Corp | Use of umbilical cord blood to treat individuals having a disease, disorder or condition |
EP1601248A2 (en) * | 2003-02-13 | 2005-12-07 | Anthrogenesis Corporation | Use of umbilical cord blood to treat individuals having a disease, disorder or condition |
US8703121B2 (en) | 2003-06-27 | 2014-04-22 | DePuy Synthes Products, LLC | Postpartum-derived cells for use in treatment of disease of the heart and circulatory system |
US10195233B2 (en) | 2003-06-27 | 2019-02-05 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
US9579351B2 (en) | 2003-06-27 | 2017-02-28 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
US10220059B2 (en) | 2003-06-27 | 2019-03-05 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
US10500234B2 (en) | 2003-06-27 | 2019-12-10 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US7875272B2 (en) | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
JP2007528702A (en) * | 2003-06-27 | 2007-10-18 | エチコン、インコーポレイテッド | Most postpartum cells derived from placental tissue and methods of making and using them. |
US9504719B2 (en) | 2003-06-27 | 2016-11-29 | DePuy Synthes Products, Inc. | Soft tissue repair and regeneration using postpartum-derived cells and cell products |
US8318483B2 (en) | 2003-06-27 | 2012-11-27 | Advanced Technologies And Regenerative Medicine, Llc | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US11191789B2 (en) | 2003-06-27 | 2021-12-07 | DePuy Synthes Products, Inc. | Cartilage and bone repair and regeneration using postpartum-derived cells |
US10383898B2 (en) | 2003-06-27 | 2019-08-20 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
US10744164B2 (en) | 2003-06-27 | 2020-08-18 | DePuy Synthes Products, Inc. | Repair and regeneration of ocular tissue using postpartum-derived cells |
US11179422B2 (en) | 2003-06-27 | 2021-11-23 | DePuy Synthes Products, Inc. | Method of differentiating umbilical cord tissue into a chondrogenic phenotype |
US11000554B2 (en) | 2003-06-27 | 2021-05-11 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
US10039793B2 (en) | 2003-06-27 | 2018-08-07 | DePuy Synthes Products, Inc. | Soft tissue repair and regeneration using postpartum-derived cells and cell products |
US10758576B2 (en) | 2003-06-27 | 2020-09-01 | DePuy Synthes Products, Inc. | Soft tissue repair and regeneration using postpartum-derived cells and cell products |
US9717763B2 (en) | 2003-06-27 | 2017-08-01 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US8580249B2 (en) | 2003-12-04 | 2013-11-12 | Regents Of The University Of Minnesota | Cell therapy for the treatment of lysosomal storage disorders |
JP2007513188A (en) * | 2003-12-04 | 2007-05-24 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Compositions and methods for the treatment of lysosomal storage diseases |
WO2005056026A1 (en) * | 2003-12-04 | 2005-06-23 | Regents Of The University Of Minnesota | Compositions and methods for the treatment of lysosomal storage disorders |
EP1708757A1 (en) * | 2003-12-19 | 2006-10-11 | Viacell, Inc. | Use of human cord blood-derived pluripotent cells for the treatment of disease |
EP1708757A4 (en) * | 2003-12-19 | 2007-01-17 | Viacell Inc | Use of human cord blood-derived pluripotent cells for the treatment of disease |
US7776586B2 (en) | 2003-12-23 | 2010-08-17 | Carag Ag | Method for isolating cells from mammary secretion |
WO2005061695A1 (en) * | 2003-12-23 | 2005-07-07 | Carag Ag | Method for isolating cells from mammary secretion |
WO2005061696A1 (en) * | 2003-12-23 | 2005-07-07 | Carag Ag | Method for isolating cells from mammary secretion |
WO2005073366A1 (en) * | 2004-01-30 | 2005-08-11 | Lifecord Inc. | Method for isolating and culturing multipotent progenitor/stem cells from umbilical cord blood and method for inducing differentiation thereof |
US7816137B2 (en) | 2004-01-30 | 2010-10-19 | Lifecord Inc. | Method for isolating and culturing multipotent progenitor cells from umbilical cord blood |
EP2312482A1 (en) | 2004-03-26 | 2011-04-20 | Celgene Corporation | Systems and methods for providing a stem cell bank |
US20120046968A1 (en) * | 2004-03-26 | 2012-02-23 | Kaminski Joseph K | Systems and methods for providing a stem cell bank |
WO2005097190A2 (en) | 2004-03-26 | 2005-10-20 | Celgene Corporation | Systems and methods for providing a stem cell bank |
US20150193581A1 (en) * | 2004-03-26 | 2015-07-09 | Celgene Corporation | Systems and methods for providing a stem cell bank |
WO2006015214A3 (en) * | 2004-07-29 | 2007-03-15 | Steenblock Res Inst Inc | Umbilical cord stem cell composition & method of treating neurological diseases |
WO2006015214A2 (en) * | 2004-07-29 | 2006-02-09 | Steenblock Research Institute, Inc. | Umbilical cord stem cell composition & method of treating neurological diseases |
US10363275B2 (en) | 2004-08-16 | 2019-07-30 | Cellresearch Corporation Pte Ltd | Isolation, cultivation and uses of stem/progenitor cells |
US9085755B2 (en) | 2004-08-16 | 2015-07-21 | Cellresearch Corporation Pte Ltd. | Isolation, cultivation and uses of stem/progenitor cells |
US7875273B2 (en) | 2004-12-23 | 2011-01-25 | Ethicon, Incorporated | Treatment of Parkinson's disease and related disorders using postpartum derived cells |
EP3031909A1 (en) * | 2005-10-13 | 2016-06-15 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
US8071376B2 (en) | 2005-10-13 | 2011-12-06 | Anthrogenesis Corporation | Production of oligodendrocytes from placenta-derived stem cells |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
US9175261B2 (en) | 2005-12-16 | 2015-11-03 | DePuy Synthes Products, Inc. | Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
WO2007079185A3 (en) * | 2005-12-29 | 2007-12-13 | Anthrogenesis Corp | Improved composition for collecting and preserving placental stem cells and methods of using the composition |
US10383897B2 (en) | 2005-12-29 | 2019-08-20 | Celularity, Inc. | Placental stem cell populations |
US9078898B2 (en) | 2005-12-29 | 2015-07-14 | Anthrogenesis Corporation | Placental stem cell populations |
WO2007079185A2 (en) * | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Improved composition for collecting and preserving placental stem cells and methods of using the composition |
US9725694B2 (en) | 2005-12-29 | 2017-08-08 | Anthrogenesis Corporation | Composition for collecting and preserving placental stem cells and methods of using the composition |
EP3486314A3 (en) * | 2005-12-29 | 2019-08-07 | Celularity, Inc. | Placental stem cell populations |
AU2014201181B2 (en) * | 2005-12-29 | 2017-07-20 | Celularity Inc. | Placental stem cell populations |
US9944900B2 (en) | 2006-01-18 | 2018-04-17 | Hemacell Perfusion | Pulsatile perfusion extraction method for non-embryonic pluripotent stem cells |
KR100871984B1 (en) | 2006-04-12 | 2008-12-05 | 주식회사 알앤엘바이오 | Multipotent Stem Cell Derived from Placenta Tissue and Cellular Therapeutic Agents Comprising the Same |
US8329468B2 (en) | 2006-05-11 | 2012-12-11 | Cord Blood Science Inc. | Methods for collecting and using placenta cord blood stem cell |
EP2023717A2 (en) * | 2006-05-11 | 2009-02-18 | Naoko Takebe | Methods for collecting and using placenta cord blood stem cells |
EP2023717A4 (en) * | 2006-05-11 | 2009-12-16 | Naoko Takebe | Methods for collecting and using placenta cord blood stem cells |
WO2007133030A1 (en) * | 2006-05-12 | 2007-11-22 | Seoul National University Industry Foundation | Multipotent adult stem cell derived from canine umbilical cord blood, placenta and canine fetus heart, method for preparing the same and cellular therapeutics containing the same |
US10066202B2 (en) | 2006-06-28 | 2018-09-04 | Rutgers, The State University Of New Jersey | Method of cryopreserving an amniotic membrane of a placenta tissue sample |
US8980630B2 (en) | 2006-06-28 | 2015-03-17 | Rutgers, The State University Of New Jersey | Obtaining multipotent amnion-derived stem cell (ADSC) from amniotic membrane tissue without enzymatic digestion |
US10407663B2 (en) | 2006-06-28 | 2019-09-10 | Rutgers, The State University Of New Jersey | Obtaining multipotent amnion-derived stem cell (ADSC) from amniotic membrane tissue without enzymatic digestion |
EP2089510A4 (en) * | 2006-06-28 | 2010-05-19 | Univ New Jersey Med | Amnion-derived stem cells and uses thereof |
EP2089510A2 (en) * | 2006-06-28 | 2009-08-19 | The University of Medicine and Dentistry of New Jersey | Amnion-derived stem cells and uses thereof |
US10105399B2 (en) | 2006-10-23 | 2018-10-23 | Celularity, Inc. | Methods and compositions for treatment of bone defects with placental cell populations |
US9339520B2 (en) | 2006-10-23 | 2016-05-17 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
US9102915B2 (en) | 2006-11-13 | 2015-08-11 | DePuy Synthes Products, Inc. | In vitro expansion of postpartum-derived cells using microcarriers |
WO2008060541A3 (en) * | 2006-11-13 | 2008-08-28 | Ethicon Inc | In vitro expansion of postpartum-derived cells using microcarriers |
US9005964B2 (en) | 2006-11-24 | 2015-04-14 | Regents Of The University Of Minnesota | Endodermal progenitor cells |
US10494607B2 (en) | 2007-02-12 | 2019-12-03 | Celularity, Inc. | CD34+,CD45−placental stem cell-enriched cell populations |
US8673547B2 (en) | 2007-03-08 | 2014-03-18 | Hemacell Perfusion, Inc. | Method for isolation of afterbirth derived cells |
US9517248B2 (en) | 2007-09-19 | 2016-12-13 | Pluristem Ltd. | Adherent cells from adipose or placenta tissues and use thereof in therapy |
US8529888B2 (en) | 2007-09-19 | 2013-09-10 | Pluristem Ltd. | Adherent cells from adipose or placenta tissues and use thereof in therapy |
WO2009061447A2 (en) * | 2007-11-07 | 2009-05-14 | Anthrogenesis Corporation | Treatment of premature birth complications |
EP3345609A1 (en) * | 2007-11-07 | 2018-07-11 | Anthrogenesis Corporation | Use of umbilical cord blood in the treatment of premature birth complications |
WO2009061447A3 (en) * | 2007-11-07 | 2010-01-21 | Anthrogenesis Corporation | Use of umbilical cord blood in the treatment of premature birth complications |
US10104880B2 (en) | 2008-08-20 | 2018-10-23 | Celularity, Inc. | Cell composition and methods of making the same |
US9758762B2 (en) | 2008-09-02 | 2017-09-12 | Pluristem Ltd. | Perfusion bioreactor for culturing CD200—placenta adherent cells |
WO2010026573A1 (en) * | 2008-09-02 | 2010-03-11 | Pluristem Ltd. | Methods of selection of cells for transplantation |
US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
US10557116B2 (en) | 2008-12-19 | 2020-02-11 | DePuy Synthes Products, Inc. | Treatment of lung and pulmonary diseases and disorders |
US9943552B2 (en) | 2009-03-26 | 2018-04-17 | DePuy Synthes Products, Inc. | hUTC as therapy for Alzheimer's disease |
WO2011093732A1 (en) | 2010-01-26 | 2011-08-04 | Stem Cells Spin S.A. | Cell homogenate from stem cells derived from growing deer antlers, a method of obtaining it and its use |
US10722541B2 (en) | 2011-03-22 | 2020-07-28 | Pluristem Ltd. | Methods for treating radiation or chemical injury |
US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
US11090339B2 (en) | 2011-06-01 | 2021-08-17 | Celularity Inc. | Treatment of pain using placental stem cells |
US9611513B2 (en) | 2011-12-23 | 2017-04-04 | DePuy Synthes Products, Inc. | Detection of human umbilical cord tissue derived cells |
US10724105B2 (en) | 2011-12-23 | 2020-07-28 | DePuy Synthes Products, Inc. | Detection of human umbilical cord tissue-derived cells |
US10047345B2 (en) | 2012-02-13 | 2018-08-14 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells with FGF4 and nicotinamide |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
WO2015051088A1 (en) * | 2013-10-03 | 2015-04-09 | Anthrogenesis Corporation | Therapy with cells from human placenta and hematopoietic cells |
WO2015073800A2 (en) | 2013-11-15 | 2015-05-21 | Anthrogenesis Corporation | Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses |
EP3068432A4 (en) * | 2013-11-15 | 2017-04-19 | Anthrogenesis Corporation | Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses |
US10184109B2 (en) | 2014-03-31 | 2019-01-22 | Sysmex Corporation | Method for obtaining differentiated cells and/or differentiated cell products from undifferentiated cell and a method of perfusion culture |
EP2937415A1 (en) * | 2014-03-31 | 2015-10-28 | Sysmex Corporation | Method for obtaining differentiated cells and/or differentiated cell products from undifferentiated cell |
FR3075818A1 (en) * | 2017-12-21 | 2019-06-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | EX-VIVO TRANSPLACENT PASSAGE STUDY SYSTEM |
EP3502233A1 (en) * | 2017-12-21 | 2019-06-26 | Institut National de la Sante et de la Recherche Medicale (INSERM) | System for studying ex-vivo transplacental transfer |
Also Published As
Publication number | Publication date |
---|---|
MXPA03007175A (en) | 2005-02-14 |
CA2856986A1 (en) | 2002-08-22 |
AU2002251935B2 (en) | 2007-11-29 |
JP2004528021A (en) | 2004-09-16 |
US20050019908A1 (en) | 2005-01-27 |
US7468276B2 (en) | 2008-12-23 |
CA2856986C (en) | 2019-08-13 |
CA2438153C (en) | 2015-06-02 |
EP2314673A1 (en) | 2011-04-27 |
US7255879B2 (en) | 2007-08-14 |
EP2336300A1 (en) | 2011-06-22 |
IL157350A0 (en) | 2004-02-19 |
EP2336301A1 (en) | 2011-06-22 |
EP1362095B1 (en) | 2015-05-27 |
CA3046566A1 (en) | 2002-08-22 |
EP2314673B1 (en) | 2013-07-24 |
CA2438153A1 (en) | 2002-08-22 |
EP1362095A2 (en) | 2003-11-19 |
EP2336300B1 (en) | 2015-07-08 |
NZ541541A (en) | 2007-04-27 |
US20040048372A1 (en) | 2004-03-11 |
US20030032179A1 (en) | 2003-02-13 |
EP2316919B1 (en) | 2015-10-07 |
EP2336301B1 (en) | 2014-07-30 |
EP2316919A1 (en) | 2011-05-04 |
EP2336299A1 (en) | 2011-06-22 |
NZ527849A (en) | 2006-09-29 |
EP2316918B1 (en) | 2015-07-01 |
WO2002064755A3 (en) | 2002-12-19 |
EP2316918A1 (en) | 2011-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2438153C (en) | Post-partum mammalian placenta, its use and placental stem cells therefrom | |
US9149569B2 (en) | Treatment of diseases or disorders using placental stem cells | |
AU2002251935A1 (en) | Post-partum mammalian placenta, its use and placental stem cells therefrom | |
ZA200306271B (en) | Post-partum mammalian placenta, its use and placental stem cells therefrom. | |
AU2020203263A1 (en) | Post-partum mammalian placenta, its use and placental stem cells therefrom | |
AU2012200069B2 (en) | Post-partum mammalian placenta, its use and placental stem cells therefrom | |
AU2007234581B2 (en) | Post-partum mammalian placenta, its use and placental stem cells therefrom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/007175 Country of ref document: MX Ref document number: 157350 Country of ref document: IL Ref document number: 2002565070 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/06271 Country of ref document: ZA Ref document number: 200306271 Country of ref document: ZA Ref document number: 2438153 Country of ref document: CA Ref document number: 1020037010671 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002251935 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 527849 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002720974 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002720974 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037010671 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2002251935 Country of ref document: AU Date of ref document: 20020213 Kind code of ref document: B |
|
WWE | Wipo information: entry into national phase |
Ref document number: 207024 Country of ref document: IL Ref document number: 207025 Country of ref document: IL |